<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis - Palser, S - 2019 | Cochrane Library</title> <meta content="Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis - Palser, S - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012300.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis - Palser, S - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012300.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012300.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatments for preventing recurrence of infection with &lt;i&gt;Pseudomonas aeruginosa&lt;/i&gt; in people with cystic fibrosis" name="citation_title"/> <meta content="Sally Palser" name="citation_author"/> <meta content="School of Medicine, University of Nottingham" name="citation_author_institution"/> <meta content="sally.palser@nottingham.ac.uk" name="citation_author_email"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Edward F Nash" name="citation_author"/> <meta content="University Hospitals Birmingham NHS Foundation Trust" name="citation_author_institution"/> <meta content="Arnav Agarwal" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="Alan R Smyth" name="citation_author"/> <meta content="School of Medicine, University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD012300.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012300.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012300.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012300.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Pseudomonas aeruginosa; Administration, Inhalation; Anti‐Bacterial Agents [*therapeutic use]; Cystic Fibrosis [*complications]; Forced Expiratory Volume; Pseudomonas Infections [*complications, drug therapy, *prevention &amp; control]; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Tobramycin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012300.pub2&amp;doi=10.1002/14651858.CD012300.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012300\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012300\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa","ms","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012300.pub2",title:"Treatments for preventing recurrence of infection with   \u003ci\u003ePseudomonas aeruginosa\u003c/i\u003e in people with cystic fibrosis",firstPublishedDate:"Dec 17, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012300.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012300.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012300.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012300.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012300.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012300.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012300.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012300.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012300.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012300.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3964 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012300.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0031"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0032"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-sec-0110"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/appendices#CD012300-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/table_n/CD012300StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/table_n/CD012300StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatments for preventing recurrence of infection with <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#CD012300-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sally Palser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#CD012300-cr-0003">Sherie Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#CD012300-cr-0004">Edward F Nash</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#CD012300-cr-0005">Arnav Agarwal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information#CD012300-cr-0006">Alan R Smyth</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information/en#CD012300-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012300.pub2">https://doi.org/10.1002/14651858.CD012300.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012300-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012300-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012300-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012300-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012300-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012300-abs-0001" lang="en"> <section id="CD012300-sec-0001"> <h3 class="title" id="CD012300-sec-0001">Background</h3> <p>Chronic infection with <i>Pseudomonas aeruginosa</i> (PA) in cystic fibrosis (CF) is a source of much morbidity and mortality. Eradication of early PA infection is possible, but can recur in many individuals. We sought to examine strategies to delay the time to PA recurrence in people with CF. </p> </section> <section id="CD012300-sec-0002"> <h3 class="title" id="CD012300-sec-0002">Objectives</h3> <p>To establish whether secondary prevention strategies, using antibiotics or other therapies, increase the chances of people with CF remaining free from PA infection following successful eradication therapy. </p> </section> <section id="CD012300-sec-0003"> <h3 class="title" id="CD012300-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched ongoing trials registries and the reference lists of relevant articles and reviews. </p> <p>Date of last search: 21 August 2019.</p> </section> <section id="CD012300-sec-0004"> <h3 class="title" id="CD012300-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (and quasi‐randomised trials where the risk of bias was low) comparing any treatment modality aimed at preventing recurrence of PA infection with placebo, standard therapy or any other treatment modality in people with CF who have undergone successful eradication of PA. </p> </section> <section id="CD012300-sec-0005"> <h3 class="title" id="CD012300-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion and risk of bias. Quality of the evidence was assessed using GRADE. Conflicts were resolved by discussion and the opinion of a third review author was sought where necessary. Only a subset of participants in the included trial were eligible, therefore individual participant data were requested and obtained from the trial investigators. </p> </section> <section id="CD012300-sec-0006"> <h3 class="title" id="CD012300-sec-0006">Main results</h3> <p>We included one trial (n = 306) in the review; however, only 253 participants had undergone successful eradication of PA, so fulfilling the inclusion criteria for our review. Information presented relates only to the included subset of participants. The trial recruited children aged one to 12 years (mean (standard deviation (SD)) age of 5.8 (3.5) years), 129 participants (51.0%) were female and the median follow‐up was 494 days. We compared cycled therapy with tobramycin inhalation solution (TIS), in which participants underwent 28 days of TIS every three months, with culture‐based therapy, in which participants were only prescribed medication when a quarterly sputum sample was positive for PA. Reasons for downgrading the quality of the evidence included applicability (only included children), incomplete outcome data and a small number of participants. </p> <p>The time to next isolation of PA was probably shorter with cycled TIS therapy than with culture‐based therapy, hazard ratio (HR) 2.04 days (95% confidence interval (CI) 1.28 to 3.26) (moderate‐quality evidence). This is in contrast to the main publication of the only included trial, which examined rate of PA positivity rather than time to PA infection and included participants not eligible for inclusion in this review. At the end of the trial, there was no difference between the cycled and culture‐based groups in the change from baseline in forced expiratory volume in one second (FEV<sub>1</sub>) L, mean difference (MD) 0.0 L (95% CI ‐0.09 to 0.09) or in FEV<sub>1</sub> % predicted, MD 0.70% (95% CI ‐4.33 to 5.73) (both very low‐quality evidence). There was no difference in the change from baseline for FVC between the groups. There was also no difference in the frequency of pulmonary exacerbations between groups, MD ‐0.18 (95% CI ‐0.51 to 0.14) (moderate‐quality evidence). Similarly, there was no difference between groups in the risk of participants developing novel resistant bacteria, RR 1.00 (95% CI 0.67 to 1.5) (moderate‐quality evidence). There were more severe adverse events in the cycled group, but the type of treatment probably makes little or no difference to the results, RR 0.65 (95% CI 0.39 to 1.11) (moderate‐quality evidence). </p> <p>There was no difference between groups in the change in weight or height from baseline or in rates of adherence to tobramycin or all trial medicines. The included trial did not assess changes in quality of life, the time to chronic infection with PA or the cost‐effectiveness of treatment. </p> </section> <section id="CD012300-sec-0007"> <h3 class="title" id="CD012300-sec-0007">Authors' conclusions</h3> <p>Cycled TIS therapy may be beneficial in prolonging the time to recurrence of PA after successful eradication, but further trials are required, specifically addressing this question and in both adults and children. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012300-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012300-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012300-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012300-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012300-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012300-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012300-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012300-abs-0004" lang="en"> <h3>Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis </h3> <p><b>Review question</b> </p> <p>We reviewed evidence about the effect of treatments given to people with cystic fibrosis (CF) to prevent recurrence of infection with bacteria called <i>Pseudomonas aeruginosa</i> (PA) after it has been successfully treated. </p> <p><b>Background</b> </p> <p>People with CF experience frequent, severe chest infections. These infections may be caused by bacteria that do not cause disease in healthy people, such as PA. PA is an important infection in CF since if it is not treated early it cannot be cleared from the lungs (termed chronic PA). When it cannot be cleared from the lungs, it causes ongoing damage to the lung tissue as well as worse chest infections. People with CF who have chronic PA may be more unwell than those without it. </p> <p>Early treatment can remove PA from the lungs of people with CF, but infection can happen again and is difficult to prevent. We want to know if giving extra treatment after the PA has been successfully treated, can prolong the time to the next infection. The treatment could be antibiotics or another treatment, for example something that helps the person's immune system fight the PA. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 21 August 2019.</p> <p><b>Trial characteristics</b> </p> <p>We included one trial with 306 participants. Only 253 of these people had had successful treatment of PA and so could be included in our review. There were only children in the trial who were aged between one and 12 years old; 51% were girls. The trial compared treatment with one month of an inhaled antibiotic every three months ('cycled treatment') with antibiotic treatment given only when the person was found to have PA ('culture‐based treatment'). People were selected randomly to have either cycled or culture‐based treatment. The trial followed people up for an average of 70 weeks. </p> <p><b>Key results</b> </p> <p>Taking into the account the certainty of the evidence, we believe that the time to the next isolation of PA was probably shorter with cycled therapy than with culture‐based therapy. We found that PA recurred in a quarter of participants in the culture‐based group by 249 days but in the cycled group it took 505 days; giving cycled treatment doubled the time to a new infection with PA compared with culture‐based treatment. This is in contrast to the main publication of the only included trial, which looked at the rate of positive PA cultures rather than the time to a new infection of PA and included participants not eligible for inclusion in this review. There was no difference between the groups in: pulmonary function (a measure of how well someone's lungs are working); in the number of people having chest infections; in the change in height and weight from the beginning to th end of the trial; in how many people took all the doses of the medications; in how many people developed infections with new bacteria; or in how many people had a serious complication. The trial did not give information about the effect of the two treatments on individuals' quality of life, the time until the development of chronic PA or the cost‐effectiveness of the treatment. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of most of the evidence was moderate. As the trial only included children, we cannot be sure if the cycled treatment would have the same effect in teenagers or adults with CF. Further trials including both adults and children are needed to help answer the question. Trials designed to specifically answer this question are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012300-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012300-sec-0116"></div> <h3 class="title" id="CD012300-sec-0117">Implications for practice</h3> <section id="CD012300-sec-0117"> <p>From the limited evidence available, cycled therapy appears to delay the recurrence of <i>Pseudomonas aeruginosa</i> (PA) after eradication in children. Further study is, however, required to better understand the benefits of cycled therapy in adolescents and adults with cystic fibrosis (CF). </p> <p>The burden of additional nebulised therapy needs to be weighed against its efficacy. We were unable to examine the effect of cycled therapy compared to culture‐based therapy on treatment burden as quality of life was not measured. Adding 28 days of nebulised therapy every three months for 15 months may seem a small addition to a therapeutic regimen, but we should bear in mind that the addition of nebulised therapy is often cited by people with CF as having a large impact on treatment burden (<a href="./references#CD012300-bbs2-0078" title="PalserSC , RaynerOC , LeightonPA , SmythAR . Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study. BMJ Open2016;6(12):e012303. ">Palser 2016</a>). </p> </section> <h3 class="title" id="CD012300-sec-0118">Implications for research</h3> <section id="CD012300-sec-0118"> <p>Now that eradication of PA is commonplace in the management of CF, further consideration needs to be made in terms of the next steps. We suggest that randomised controlled trials, specifically dedicated to investigating the prevention of PA recurrence, are needed. These trials must be conducted in participants of all ages with CF. Treatments other than antimicrobial agents, which reduce the chance of recurrence by improving host defence or exposure to the organism, could also be considered. </p> <p>Success in treating infection in CF may necessitate the use of surrogate markers, as evidenced by Treggiari (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). In this trial, the median time to recurrence of PA could not be determined in a trial with a planned 15‐month follow‐up and time to chronic PA would require even longer follow‐up. Time to next pulmonary exacerbation may be the most pragmatic outcome and would facilitate comparisons with other CF pathogens. However, as discussed above, the use of time to recurrence as the primary outcome measure meant that Treggiari reported no difference in the two treatment groups; whilst we have shown a hazard ratio of 2.04 in the time to recurrence of PA for those undergoing culture‐based therapy compared to cycled therapy. </p> <p>In addition to time to chronic PA infection and time to next pulmonary exacerbation, outcomes to be included in future trials of interventions to prevent PA recurrence should include, lung function, nutritional parameters, cost‐effectiveness and quality of life including treatment burden. </p> <p>Since delaying the onset of chronic PA infection may reduce the longer‐term morbidity and mortality of CF, assessing these outcomes would require longer durations of observation than are feasible in a traditional RCT. We therefore suggest consideration of alternative trial designs such as registry‐based trials may be the best way to examine these outcomes. </p> <p>These trials need to use internationally standardised definitions for:</p> <p> <ol id="CD012300-list-0013"> <li> <p>chronic PA infection;</p> </li> <li> <p>pulmonary exacerbations;</p> </li> <li> <p>eradication of PA.</p> </li> </ol> </p> <p>Development and widespread use of these definitions will improve the comparability of trials, strengthening the conclusions which can be drawn when they are compared and would form part of a core outcome set for CF. The importance of a core outcome set to reduce selective reporting bias and thereby improve the validity of systematic review in CF has previously been highlighted (<a href="./references#CD012300-bbs2-0047" title="DwanK , KirkhamJJ , WilliamsonPR , GambleC . Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. BMJ Open2013;3(6):e002709. ">Dwan 2013</a>). The results of the Core Outcome Set Taskforce for CF (COST‐CF) will be an important development in the care of people with CF (<a href="./references#CD012300-bbs2-0095" title="SmythA . The Core Outcome Set for CF (COST‐CF). www.comet‐initiative.org/studies/details/882?result=true. COMET Initiative, (accessed prior to 29 July 2019). ">Smyth 2017</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012300-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012300-sec-0022"></div> <div class="table" id="CD012300-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: cycled versus culture‐based antibiotic therapy for preventing recurrence of infection with Pseudomonas aeruginosa </span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cycled antibiotic therapy compared with culture based antibiotic therapy for preventing recurrence of infection with PA in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (aged 1 to 12 years) with CF and a newly isolated PA infection </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: cycled administration of antibiotics </p> <p><b>Comparison</b>: culture‐based administration of antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Culture‐based therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cycled therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to next isolation of PA</b> </p> <p>Follow‐up: up to 583 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The participants in the culture‐based therapy group were twice as likely to have experienced a recurrence by their final study visit than those in the cycled group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR <b>2.04</b> (1.28 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR was calculated from individual patient data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline (L) </p> <p>Follow‐up: median 494 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in FEV<sub>1</sub> in the culture based group from baseline was +0.26 L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in FEV<sub>1</sub> in the cycled group was 0L higher (0.09 L lower to 0.09 L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between the two groups was not statistically significant P = 0.97.</p> <p>FEV<sub>1</sub> was also measured in percent predicted which showed a non‐significant difference between the groups at up to two years. MD 0.7% (‐4.33% to 5.73%) P = 0.79. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b>: frequency </p> <p>Follow‐up: up to 583 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of pulmonary exacerbation in the culture‐based group was 1.1.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of pulmonary exacerbation in the cycled group was 0.18 pulmonary exacerbations per person lower (0.51 lower to 0.14 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between the groups was not statistically significant, P = 0.27.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to chronic PA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: severe adverse events (total) </p> <p>Follow‐up: 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><br/> (90 to 256) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> (0.39 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups for the total number of participants experiencing a serious adverse event P = 0.11. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of novel bacteria</b>: isolation of novel gram negative organisms </p> <p>Follow‐up: median 494 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b><br/> (185 to 414) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> </p> <p><b>1.0</b> </p> <p>(0.67 to 1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference in the acquisition of novel organisms between treatment groups. P = 0.98 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CF</b> : cystic fibrosis; <b>CI</b> : confidence interval; <b>HR</b> : hazard ratio; <b>RR</b> : risk ratio; <b>PA</b>: <i>Pseudomonas aeruginosa.</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to indirectness. The trial only includes children between the ages of one and 12 years and was not designed to answer the specific question posed in this review. </p> <p>2. Downgraded once due to risk of bias from incomplete outcome data. Although this was taken from individual patient data, only 131 of the 253 participants included in our subset, were included in this analysis. </p> <p>3. Downgraded once from small participant numbers which do not meet the optimum information size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012300-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012300-sec-0023"></div> <section id="CD012300-sec-0024"> <h3 class="title" id="CD012300-sec-0024">Description of the condition</h3> <p>Cystic fibrosis (CF) is the commonest autosomal recessive, life‐limiting condition in white populations, affecting between 70,000 (<a href="./references#CD012300-bbs2-0040" title="CF Foundation. About Cystic Fibrosis. www.cff.org/What‐is‐CF/About‐Cystic‐Fibrosis/ (accessed 08 December 2015). ">Cystic Fibrosis Foundation 2015</a>) and 100,000 people (<a href="./references#CD012300-bbs2-0043" title="Cystic FibrosisTrust . About CF, frequently asked questions. www.cysticfibrosis.org.uk/about‐cf/frequently‐asked‐questions#na (accessed 08 December 2015). ">Cystic Fibrosis Trust 2015</a>) worldwide. It is caused by defects in the gene coding for an epithelial ion channel, the cystic fibrosis transmembrane conductance regulator (CFTR). Clinically, the disease affects multiple systems with most of the morbidity and mortality stemming from the respiratory effects. A cycle of recurrent infection, inflammation and progressive lung damage ultimately results in respiratory failure which is the primary cause of death (<a href="./references#CD012300-bbs2-0041" title="Cystic Fibrosis Foundation [US]. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. www.cff.org/Research/Researcher‐Resources/Patient‐Registry/2017‐Patient‐Registry‐Annual‐Data‐Report.pdf. Bethesda, Maryland, (accessed prior to 29 July 2019). ">Cystic Fibrosis Foundation 2018</a>). The current median age of death in people with CF in the UK is 31 years (<a href="./references#CD012300-bbs2-0044" title="Cystic FibrosisTrust . UK Cystic Fibrosis Registry Annual Data Report 2017. www.cysticfibrosis.org.uk/the‐work‐we‐do/uk‐cf‐registry/reporting‐and‐resources. London: Cystic Fibrosis Trust, (accessed prior to 27 July 2019). ">Cystic Fibrosis Trust 2018</a>) and 30.7 years in the USA (<a href="./references#CD012300-bbs2-0041" title="Cystic Fibrosis Foundation [US]. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. www.cff.org/Research/Researcher‐Resources/Patient‐Registry/2017‐Patient‐Registry‐Annual‐Data‐Report.pdf. Bethesda, Maryland, (accessed prior to 29 July 2019). ">Cystic Fibrosis Foundation 2018</a>), although the life expectancy of children born in 2000 is predicted to be over 50 years (<a href="./references#CD012300-bbs2-0046" title="DodgeJA , LewisPA , StantonM , WilsherJ . Cystic fibrosis mortality and survival in the UK: 1947‐2003. European Respiratory Journal2007;29(3):522‐6. ">Dodge 2007</a>). </p> <p>Respiratory infections in CF occur from infancy. By the age of three years 50% of children will have had an initial infection with <i>Pseudomonas aeruginosa</i> (PA) (<a href="./references#CD012300-bbs2-0065" title="JonesP , PalserSC , PrayleAP , HurleyMN , SmythAR . Secular trends in Pseudomonas aeruginosa acquisition in the United Kingdom: a registry study. Journal of Cystic Fibrosis2015;14 Supp 1:S31. [Abstract no.: WS20.1] ">Jones 2015</a>). In the UK, half of people with CF (pwCF) have chronic infection with PA by their mid‐twenties (<a href="./references#CD012300-bbs2-0044" title="Cystic FibrosisTrust . UK Cystic Fibrosis Registry Annual Data Report 2017. www.cysticfibrosis.org.uk/the‐work‐we‐do/uk‐cf‐registry/reporting‐and‐resources. London: Cystic Fibrosis Trust, (accessed prior to 27 July 2019). ">Cystic Fibrosis Trust 2018</a>). </p> <p>If PA is neither spontaneously cleared nor eradicated with antibiotic therapy, the CF lung environment facilitates PA adaptation to a mucoid phenotype (bacteria embedded in a sticky gel) (<a href="./references#CD012300-bbs2-0048" title="DöringG . Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. International Journal of Medical Microbiology2010;300(8):573‐7. [DOI: 10.1016/j.ijmm.2010.08.010] ">Döring 2010</a>; <a href="./references#CD012300-bbs2-0082" title="PittTL . Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. Journal of the Royal Society of Medicine1986;79 Suppl 12:13‐8. ">Pitt 1986</a>). These organisms become embedded in an exopolysaccharide biofilm which protects the organism from phagocytosis (ingestion of the bacteria by an immune cell) and reduces the efficacy of antimicrobial agents (<a href="./references#CD012300-bbs2-0097" title="SpeertDP , FarmerSW , CampbellME , MusserJM , SelanderRK , KuoS . Conversion of Pseudomonas aeruginosa to the phenotype characteristic of strains from patients with cystic fibrosis. Journal of Clinical Microbiology1990;28(2):188‐94. ">Speert 1990</a>). Once this change has occurred, the mucoid PA is virtually impossible to eradicate (<a href="./references#CD012300-bbs2-0034" title="BurnsJL , GibsonRL , McNamaraS , YimD , EmersonJ , RosenfeldM , et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases2001;183(3):444‐52. ">Burns 2001</a>; <a href="./references#CD012300-bbs2-0048" title="DöringG . Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. International Journal of Medical Microbiology2010;300(8):573‐7. [DOI: 10.1016/j.ijmm.2010.08.010] ">Döring 2010</a>; <a href="./references#CD012300-bbs2-0057" title="HogardtM , HeesemannJ . Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. International Journal of Medical Microbiology2010;300(8):557‐62. [DOI: 10.1016/j.ijmm.2010.08.008] ">Hogardt 2010</a>; <a href="./references#CD012300-bbs2-0059" title="HøibyN , FrederiksenB , PresslerT . Eradication of early Pseudomonas aeruginosa infection. Journal of Cystic Fibrosis2005;4 Suppl 2:49‐54. ">Høiby 2005</a>; <a href="./references#CD012300-bbs2-0082" title="PittTL . Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. Journal of the Royal Society of Medicine1986;79 Suppl 12:13‐8. ">Pitt 1986</a>). If the PA infection cannot be cleared, the affected person is faced with an increased treatment burden, accelerated decline in lung function (<a href="./references#CD012300-bbs2-0049" title="EmersonJ , RosenfeldM , McNamaraS , RamseyB , GibsonRL . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology2002;34(2):91‐100. ">Emerson 2002</a>; <a href="./references#CD012300-bbs2-0069" title="KonstanMW , MorganWJ , ButlerSM , PastaDJ , CraibML , SilvaSJ , et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. Journal of Pediatrics2007;151(2):134‐9, 139 e1. ">Konstan 2007</a>; <a href="./references#CD012300-bbs2-0070" title="KosorokMR , ZengL , WestSE , RockMJ , SplaingardML , LaxovaA , et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology2001;32(4):277‐87. ">Kosorok 2001</a>), increased symptom severity (<a href="./references#CD012300-bbs2-0077" title="NixonGM , ArmstrongDS , CarzinoR , CarlinJB , OlinskyA , RobertsonCF , et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. Journal of Pediatrics2001;138(5):699‐704. ">Nixon 2001</a>; <a href="./references#CD012300-bbs2-0101" title="ZemanickET , EmersonJ , ThompsonV , McNamaraS , MorganW , GibsonRL , et al. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatric Pulmonology2015;50(1):42‐8. [DOI: 10.1002/ppul.23036] ">Zemanick 2015</a>) and increased mortality (<a href="./references#CD012300-bbs2-0049" title="EmersonJ , RosenfeldM , McNamaraS , RamseyB , GibsonRL . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatric Pulmonology2002;34(2):91‐100. ">Emerson 2002</a>). </p> <section id="CD012300-sec-0025"> <h4 class="title">Acquisition of PA</h4> <p>PA is an environmental organism and an opportunistic human pathogen ‐ infection typically occurs where host defences are weakened. Early isolates usually have features common to environmental organisms (<a href="./references#CD012300-bbs2-0034" title="BurnsJL , GibsonRL , McNamaraS , YimD , EmersonJ , RosenfeldM , et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases2001;183(3):444‐52. ">Burns 2001</a>); therefore, the commonest source of infection is believed to be environmental. The organism is present in soil (<a href="./references#CD012300-bbs2-0080" title="PeetersC , DepoorterE , PraetJ , VandammeP . Extensive cultivation of soil and water samples yields various pathogens in patients with cystic fibrosis but not Burkholderia multivorans. Journal of Cystic Fibrosis2016;15(6):769‐75. [DOI: 10.1016/j.jcf.2016.02.014] ">Peeters 2016</a>) and both fresh and salt water (<a href="./references#CD012300-bbs2-0066" title="KhanNH , IshiiY , Kimata‐KinoN , EsakiH , NishinoT , NishimuraM , et al. Isolation of Pseudomonas aeruginosa from open ocean and comparison with freshwater, clinical, and animal isolates. Microbial Ecology2007;53(2):173‐86. ">Khan 2007</a>; <a href="./references#CD012300-bbs2-0081" title="PirnayJP , MatthijsS , ColakH , ChablainP , BilocqF , VanEldereJ , et al. Global Pseudomonas aeruginosa biodiversity as reflected in a Belgian river. Environmental Microbiology2005;7(7):969‐80. ">Pirnay 2005</a>). Strains of PA identical to those isolated from newly infected pwCF were found in the homes of nine out of 50 pwCF; however, the temporal relationship of these isolates is unknown (<a href="./references#CD012300-bbs2-0092" title="SchelstraeteP , VanDaeleS , DeBoeckK , ProesmansM , LebecqueP , Leclercq‐FoucartJ , et al. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients. European Respiratory Journal2008;31(4):822‐9. ">Schelstraete 2008</a>). Other potential sources identified are hot tubs (<a href="./references#CD012300-bbs2-0051" title="GovanJR , NelsonJW . Microbiology of lung infection in cystic fibrosis. British Medical Bulletin1992;48(4):912‐30. ">Govan 1992</a>) and dental equipment (<a href="./references#CD012300-bbs2-0033" title="BarbenJ , SchmidJ . Dental units as infection sources of Pseudomonas aeruginosa. European Respiratory Journal2008;32(4):1122‐3. ">Barben 2008</a>; <a href="./references#CD012300-bbs2-0061" title="JensenET , GiwercmanB , OjeniyiB , BangsborgJM , HansenA , KochC , et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. Journal of Hospital Infection1997;36(2):117‐22. ">Jensen 1997</a>; <a href="./references#CD012300-bbs2-0072" title="MainzJG , GerberA , LorenzM , MichlR , HentschelJ , NaderA , et al. Pseudomonas aeruginosa acquisition in cystic fibrosis patients in context of otorhinolaryngological surgery or dentist attendance: case series and discussion of preventive concepts. Case Reports in Infectious Diseases2015;2015:438517. [DOI: 10.1155/2015/438517] ">Mainz 2015</a>). </p> <p>Environmental conditions may affect PA acquisition. Psoter found an association between increasing exposure to fine particulate matter in the atmosphere and earlier acquisition of PA (<a href="./references#CD012300-bbs2-0084" title="PsoterKJ , DeRoosAJ , MayerJD , KaufmanJD , WakefieldJ , RosenfeldM . Fine particulate matter exposure and initial Pseudomonas aeruginosa acquisition in cystic fibrosis. Annals of the American Thoracic Society2015;12(3):385‐91. [DOI: 10.1513/AnnalsATS.201408‐400OC] ">Psoter 2015</a>). Ambient temperature may also have an effect. Research from Denmark from the early 1990s suggested PA infection peaked in the winter months (<a href="./references#CD012300-bbs2-0062" title="JohansenHK , HoibyN . Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax1992;47:109‐11. ">Johansen 1992</a>). However, in 2013 Psoter showed an increased incidence of infection in the summer and autumn (<a href="./references#CD012300-bbs2-0083" title="PsoterKJ , DeRoosAJ , WakefieldJ , MayerJ , RosenfeldM . Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clinical Microbiology and Infection2013;19(11):E483‐9. ">Psoter 2013</a>). Other investigators found that pwCF living in areas with higher ambient temperatures have a higher prevalence of PA, and acquire it earlier, than those living in cooler climates (<a href="./references#CD012300-bbs2-0038" title="CollacoJM , McGreadyJ , GreenDM , NaughtonKM , WatsonCP , ShieldsT , et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One2011;6(11):e27784. ">Collaco 2011</a>). </p> <p>Certain strains of PA are transmissible between pwCF (<a href="./references#CD012300-bbs2-0035" title="ChengK , SmythRL , GovanJR , DohertyC , WinstanleyC , DenningN , et al. Spread of beta‐lactam‐resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet1996;348(9028):639‐42. ">Cheng 1996</a>; <a href="./references#CD012300-bbs2-0063" title="JonesAM , GovanJR , DohertyCJ , DoddME , IsalskaBJ , StanbridgeTN , et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet2001;358(9281):557‐8. ">Jones 2001</a>). This understanding led to the introduction of patient segregation, though the risk of transmission is low without long‐term close contact (<a href="./references#CD012300-bbs2-0096" title="SpeertDP , CampbellME . Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Hospital Infection1987;9(1):11‐21. ">Speert 1987</a>; <a href="./references#CD012300-bbs2-0098" title="SpeertDP , CampbellME , HenryDA , MilnerR , TahaF , GravelleA , et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. American Journal of Respiratory and Critical Care Medicine2002;166(7):988‐93. ">Speert 2002</a>). Nosocomial PA spread in hospitals is a source of major concern, though studies have failed to find a reservoir (<a href="./references#CD012300-bbs2-0064" title="JonesAM , GovanJR , DohertyCJ , DoddME , IsalskaBJ , StanbridgeTN , et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax2003;58:525‐7. ">Jones 2003</a>; <a href="./references#CD012300-bbs2-0079" title="PanageaS , WinstanleyC , WalshawMJ , LedsonMJ , HartCA . Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. Journal of Hospital Infection2005;59(2):102‐7. ">Panagea 2005</a>). </p> <p>Isolates of PA have been identified in air samples taken from rooms with PA‐positive pwCF (<a href="./references#CD012300-bbs2-0064" title="JonesAM , GovanJR , DohertyCJ , DoddME , IsalskaBJ , StanbridgeTN , et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax2003;58:525‐7. ">Jones 2003</a>) and these can survive in airborne droplet nuclei (less than 10 μm diameter), supporting a possible airborne route of PA transmission (<a href="./references#CD012300-bbs2-0037" title="CliftonIJ , FletcherLA , BeggsCB , DentonM , PeckhamDG . A laminar flow model of aerosol survival of epidemic and non‐epidemic strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. BMC Microbiology2008;8:105. ">Clifton 2008</a>). Knibbs subsequently demonstrated that cough aerosols generated by pwCF positive for PA contain viable organisms, which remain detectable at a distance of four metres and after 45 minutes (<a href="./references#CD012300-bbs2-0067" title="KnibbsLD , JohnsonGR , KiddTJ , CheneyJ , GrimwoodK , KattenbeltJA , et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax2014;69(8):740‐5. [DOI: 10.1136/thoraxjnl‐2014‐205213] ">Knibbs 2014</a>). </p> </section> <section id="CD012300-sec-0026"> <h4 class="title">Detection of PA</h4> <p>Microbiological samples are commonly collected from pwCF at routine clinic appointments and at the time of a pulmonary exacerbation. The frequency of this sampling depends on national practices. Early identification of PA infection allows for eradication therapy, since at acquisition the bacterial load is usually low and the organism non‐mucoid and relatively sensitive to antibiotics (<a href="./references#CD012300-bbs2-0034" title="BurnsJL , GibsonRL , McNamaraS , YimD , EmersonJ , RosenfeldM , et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases2001;183(3):444‐52. ">Burns 2001</a>; <a href="./references#CD012300-bbs2-0048" title="DöringG . Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. International Journal of Medical Microbiology2010;300(8):573‐7. [DOI: 10.1016/j.ijmm.2010.08.010] ">Döring 2010</a>). </p> <p>The preferred sampling method is a sputum sample, but in many cases this is not possible. Where the individual does not produce sputum, options include cough swabs, oropharyngeal culture (OPC), induced sputum and bronchoalveolar lavage (BAL) (<a href="./references#CD012300-bbs2-0042" title="UK Cystic FibrosisTrust . Antibiotic Treatment for Cystic Fibrosis – 3rd edition. Report of the UK Cystic Fibrosis Trust Antibiotic Group. www.cysticfibrosis.org.uk/media/82010/antibiotic‐treatment‐for‐cystic‐fibrosis‐may‐09.pdf (accessed 08 December 2015). ">Cystic Fibrosis Trust 2009</a>). </p> <p>Non‐sputum techniques have a number of disadvantages. The gold standard is BAL, but this is invasive and requires sedation or an anaesthetic and selective sampling may miss organisms. Any OPC positive for PA may reflect oral flora, rather than being truly representative of the lower airways (<a href="./references#CD012300-bbs2-0090" title="RosenfeldM , EmersonJ , AccursoF , ArmstrongD , CastileR , GrimwoodK , et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatric Pulmonology1999;28(5):321‐8. ">Rosenfeld 1999</a>). The diagnostic accuracy of OPC cultures is poor (<a href="./references#CD012300-bbs2-0086" title="RamseyBW , WentzKR , SmithAL , RichardsonM , Williams‐WarrenJ , HedgesDL , et al. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. American Review of Respiratiry Disease1991;144(2):331‐7. ">Ramsey 1991</a>), but many studies continue to use OPC sampling for practical reasons. Induced sputum has been performed in children as young as six months and samples can be collected successfully in 84% of procedures. Sensitivity is as good as two lobe bronchoalveolar lavage (<a href="./references#CD012300-bbs2-0089" title="RonchettiK , TameJD , PaiseyC , ThiaLP , DoullI , HoweR , et al. The CF‐Sputum Induction Trial (CF‐SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial. Lancet Respiratory Medicine2018;6(6):461‐71. ">Ronchetti 2018</a>). </p> <p>For the purposes of this review therefore, detection of PA is defined as the detection of PA in any respiratory sample; however, PA serology alone will not be accepted as evidence of new infection. First infection with PA is defined as the lifetime first identification of PA in any respiratory sample. </p> </section> <section id="CD012300-sec-0027"> <h4 class="title">Eradication of PA</h4> <p>Early antibiotic therapy is effective in reducing the chance of chronic infection. A Cochrane Review showed that a number of antibiotic regimens are more effective than no treatment at eradicating PA, with an effect that can be sustained for up to two years (<a href="./references#CD012300-bbs2-0071" title="Langton HewerSC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD004197.pub5] ">Langton Hewer 2017</a>). The current review follows on from this work, focusing on additional treatments given after successful eradication to prevent or delay recurrent PA acquisition in pwCF. </p> <p>Many studies of PA eradication use a negative respiratory culture at the end of the active treatment period to define successful eradication. The definition of eradication is crucial to understand whether a subsequent positive PA sample is truly a new infection, rather than an incompletely cleared index episode. </p> <p>Up to 90% of individuals will clear their first infection, but further episodes of intermittent infection commonly occur over the subsequent months to years until chronic infection is finally established (<a href="./references#CD012300-bbs2-0059" title="HøibyN , FrederiksenB , PresslerT . Eradication of early Pseudomonas aeruginosa infection. Journal of Cystic Fibrosis2005;4 Suppl 2:49‐54. ">Høiby 2005</a>). This recurrence may be with a new strain, or with the same strain of PA, indicating either ineffective eradication or re‐infection from a common source. One observational study reported that 19 pwCF followed up after successful eradication had recurrent infection within a median (standard deviation (SD)) time of 8 (5.7) months (range 3 to 25 months) (<a href="./references#CD012300-bbs2-0075" title="MunckA , BonacorsiS , Mariani‐KurkdjianP , LebourgeoisM , GerardinM , BrahimiN , et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatric Pulmonology2001;32(4):288‐92. ">Munck 2001</a>). In 14 out of the 19 pwCF, the new PA strain had a distinct genotypic profile and researchers concluded that the initial eradication therapy had successfully eradicated the PA infection, with the subsequent infection considered a separate event (<a href="./references#CD012300-bbs2-0075" title="MunckA , BonacorsiS , Mariani‐KurkdjianP , LebourgeoisM , GerardinM , BrahimiN , et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatric Pulmonology2001;32(4):288‐92. ">Munck 2001</a>). In contrast, in a further study of 41 pwCF who were followed after a first ever PA isolation, 18 re‐acquired PA after a median of 7.5 months (range 2 to 55 months), 11 of whom had identical genotypes at the second isolate (<a href="./references#CD012300-bbs2-0093" title="SchelstraeteP , DeschaghtP , VanSimaeyL , VanDaeleS , HaerynckF , VaneechoutteM , et al. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. Journal of Cystic Fibrosis2010;9(2):99‐103. ">Schelstraete 2010</a>). </p> </section> </section> <section id="CD012300-sec-0028"> <h3 class="title" id="CD012300-sec-0028">Description of the intervention</h3> <p>The effect of antibiotic regimens to eradicate initial PA infection may be sustained for up to two years, but the risk of a future episode of infection remains (<a href="./references#CD012300-bbs2-0071" title="Langton HewerSC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD004197.pub5] ">Langton Hewer 2017</a>). Currently, individuals who have successfully eradicated PA revert to their pre‐eradication treatment regimens and no ongoing secondary prevention is attempted. </p> <p>Secondary prevention is the early identification and treatment of health problems prior to the appearance of symptoms (<a href="./references#CD012300-bbs2-0060" title="Institute for Work and Health. What researchers mean by Primary, Secondary and Tertiary Prevention. At Work2015;Spring 2015:2. ">Institute for Work and Health 2015</a>). This contrasts with primary prevention in which mechanisms are applied to the whole population or a targeted, at‐risk, population to prevent an illness or event occurring. Examples of secondary prevention in the setting of infection include cotrimoxazole prophylaxis to prevent pneumonia caused by <i>Pneumocystis jiroveci</i> in immunosuppressed patients (<a href="./references#CD012300-bbs2-0036" title="CheungYF , ChanCF , LeeCW , LauYL . An outbreak of pneumocystis carinii pneumonia in children with malignancy. Journal of Paediatrics and Child Health1994;30(2):173‐5. ">Cheung 1994</a>) or the use of antiviral agents to prevent recurrent episodes of herpes simplex infection in people with HIV (<a href="./references#CD012300-bbs2-0076" title="NelsonM , DockrellD , EdwardsS , AngusB , BartonS , BeechingN , et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV‐seropositive individuals 2011. HIV Medicine2011;12 Suppl 2:1‐140. [DOI: 10.1111/j.1468‐1293.2011.00944_1.x] ">Nelson 2011</a>). </p> <p>Host factors, such as sputum rheology and mucus plugging, may be equally important in the re‐acquisition of PA. Interventions which affect these host factors, e.g. recombinant dornase alfa (rhDNase) or hypertonic saline may also have an effect on recurrence. Treatment of eligible pwCF with CFTR modulators may have an effect on the acquisition and eradication of PA; in a study from the USA the chance of a person having positive PA cultures was significantly reduced after commencing treatment with ivacaftor (<a href="./references#CD012300-bbs2-0053" title="HeltsheSL , Mayer‐HamblettN , BurnsJL , KhanU , BainesA , RamseyBW , et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D‐CFTR treated with ivacaftor. Clinical Infectious Disease2015;60(5):703‐12. ">Heltshe 2015</a>). The administration of a further course of oral, inhaled or intravenous antibiotics, after eradication of PA is complete, may reduce the risk of recurrent infection. It is possible that CFTR modulators may affect PA isolation after eradication (<a href="./references#CD012300-bbs2-0053" title="HeltsheSL , Mayer‐HamblettN , BurnsJL , KhanU , BainesA , RamseyBW , et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D‐CFTR treated with ivacaftor. Clinical Infectious Disease2015;60(5):703‐12. ">Heltshe 2015</a>). Finally, immunotherapy such as IgY (derived from the eggs of hens immunised against PA) may have a role in secondary prevention (<a href="./references#CD012300-bbs2-0068" title="KollbergH , CarlanderD , OlesenH , WejåkerP , JohannessonM , LarssonA . Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatric Pulmonology2003;35(6):433‐40. ">Kollberg 2003</a>). </p> </section> <section id="CD012300-sec-0029"> <h3 class="title" id="CD012300-sec-0029">How the intervention might work</h3> <p>In people with established PA infection, antibiotics are used to reduce inflammation, to maintain lung function and to reduce the chance of a pulmonary exacerbation (<a href="./references#CD012300-bbs2-0042" title="UK Cystic FibrosisTrust . Antibiotic Treatment for Cystic Fibrosis – 3rd edition. Report of the UK Cystic Fibrosis Trust Antibiotic Group. www.cysticfibrosis.org.uk/media/82010/antibiotic‐treatment‐for‐cystic‐fibrosis‐may‐09.pdf (accessed 08 December 2015). ">Cystic Fibrosis Trust 2009</a>; <a href="./references#CD012300-bbs2-0073" title="MogayzelPJJr , NaureckasET , RobinsonKA , BradyC , GuillM , LahiriT , et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Annals of the American Thoracic Society2014;11(10):1640‐50. [DOI: 10.1513/AnnalsATS.201404‐166OC] ">Mogayzel 2014</a>). These antibiotics are administered orally, via nebuliser or in combination with the addition of regular cycled intravenous antibiotics as the disease course progresses (<a href="./references#CD012300-bbs2-0042" title="UK Cystic FibrosisTrust . Antibiotic Treatment for Cystic Fibrosis – 3rd edition. Report of the UK Cystic Fibrosis Trust Antibiotic Group. www.cysticfibrosis.org.uk/media/82010/antibiotic‐treatment‐for‐cystic‐fibrosis‐may‐09.pdf (accessed 08 December 2015). ">Cystic Fibrosis Trust 2009</a>). </p> <p>In a retrospective study looking at nebulised gentamicin as primary prevention for the acquisition of PA, children meeting high‐risk criteria for the development of PA infection were treated for a period of three years (<a href="./references#CD012300-bbs2-0052" title="HeinzlB , EberE , OberwaldnerB , HaasG , ZachMS . Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatric Pulmonology2002;33(1):32‐7. ">Heinzel 2002</a>). In the event of a further high‐risk incident, treatment was continued until three years after the last high‐risk event. A final audit of these children in 1999 showed that all those who continued on inhaled gentamicin remained free of PA, while seven out of 16 children who stopped prophylaxis (preventative treatment) developed chronic infection (P = 0.01). </p> <p>Secondary prevention in the form of a similar prolonged course of treatment could sustain the benefits achieved by eradication, delaying the development of chronic PA infection and the subsequent negative consequences. </p> </section> <section id="CD012300-sec-0030"> <h3 class="title" id="CD012300-sec-0030">Why it is important to do this review</h3> <p>Long‐term antibiotic therapy may be beneficial in delaying chronic PA infection, but it exposes individuals to the risk of adverse events (side effects of treatment, e.g. allergy, damage to hearing or kidney function). Furthermore, the burden of treatment is one reason that PA is feared by people with CF and their families (<a href="./references#CD012300-bbs2-0078" title="PalserSC , RaynerOC , LeightonPA , SmythAR . Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study. BMJ Open2016;6(12):e012303. ">Palser 2016</a>). The use of prophylactic antibiotics, particularly nebulised, in people with established chronic PA can impact on school, work and social life (<a href="./references#CD012300-bbs2-0039" title="ConwaySP , PondMN , HamnettT , WatsonA . Compliance with treatment in adult patients with cystic fibrosis. Thorax1996;51(1):29‐33. ">Conway 1996</a>). As such, strong evidence as to the efficacy of long‐term antibiotic treatment is essential before it can be advocated to people with CF. In the current financial climate it is also important to assess the cost‐benefit of such potential treatments, particularly as the prognosis of people with CF continues to improve (<a href="./references#CD012300-bbs2-0058" title="HurleyMN , McKeeverTM , PrayleAP , FogartyAW , SmythAR . Rate of improvement of CF life expectancy exceeds that of general population‐‐observational death registration study. Journal of Cystic Fibrosis2014;13(4):410‐5. [DOI: 10.1016/j.jcf.2013.12.002] ">Hurley 2014</a>). </p> <p>We will therefore examine current evidence to assess the safety, tolerability and cost‐effectiveness of secondary prevention strategies proposed to prevent recurrent PA infection in pwCF. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012300-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012300-sec-0031"></div> <p>To establish whether secondary prevention strategies, using antibiotics or other therapies, increase the chances of pwCF remaining free from PA infection following successful eradication therapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012300-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012300-sec-0032"></div> <section id="CD012300-sec-0033"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012300-sec-0034"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), published or unpublished and in any language were eligible for inclusion. Quasi‐RCTs were eligible for inclusion if the review authors were satisfied that the groups were similar at baseline. </p> </section> <section id="CD012300-sec-0035"> <h4 class="title">Types of participants</h4> <p>pwCF, diagnosed clinically or by genetic or sweat testing. Each participant must have had an episode of PA within the last six months which was successfully treated with an eradication regimen. They must have remained free of infection with PA between the end of eradication and start of treatment for ongoing prevention. </p> </section> <section id="CD012300-sec-0036"> <h4 class="title">Types of interventions</h4> <p>In pwCF in whom PA was successfully eradicated, we compared a time‐limited course of therapy (for antimicrobials this could be oral, inhaled or intravenous or any combination of these) to prevent a recurrent infection with the organism to usual care, placebo or another therapeutic strategy. Time‐limited therapy included all treatment in which a specific duration was pre‐specified. Time‐limited therapy included regimens where the treatment was intermittent but continued at specified intervals for a defined duration. Long‐term suppressive therapy, given for an indefinite period, was not considered. </p> </section> <section id="CD012300-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD012300-sec-0038"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012300-list-0001"> <li> <p>Time to next isolation of PA (identified by any method, e.g. sputum culture (spontaneous or induced), BAL or OP culture and as defined by the trial investigators) </p> </li> </ol> </p> </section> <section id="CD012300-sec-0039"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012300-list-0002"> <li> <p>Change in quality of life (QoL) from baseline (as measured by a validated tool (e.g. the Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) (<a href="./references#CD012300-bbs2-0085" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire‐Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610‐8. ">Quittner 2009</a>), the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) (<a href="./references#CD012300-bbs2-0050" title="GeeL , AbbottJ , ConwayS , EtheringtonC , WebbA . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946‐54. ">Gee 2000</a>) or any other validated tool) </p> </li> <li> <p>Change (absolute and relative) from baseline for pulmonary function tests</p> <ol id="CD012300-list-0003"> <li> <p>forced expiratory volume in one second (FEV<sub>1</sub>) measured in both L and % predicted </p> </li> <li> <p>forced vital capacity (FVC) measured in both L and % predicted</p> </li> </ol> </li> <li> <p>Pulmonary exacerbations</p> <ol id="CD012300-list-0004"> <li> <p>time to next exacerbation</p> </li> <li> <p>frequency of exacerbations</p> </li> <li> <p>number of days in hospital</p> </li> </ol> </li> <li> <p>Nutritional parameters ‐ change from baseline</p> <ol id="CD012300-list-0005"> <li> <p>weight (kg) and weight centile or Z score</p> </li> <li> <p>height (cm) (children) and height centile or Z score</p> </li> <li> <p>body mass index (BMI) and BMI centile</p> </li> </ol> </li> <li> <p>Time to chronic PA infection (as defined by the trial investigators)</p> </li> <li> <p>Adherence to treatment</p> <ol id="CD012300-list-0006"> <li> <p>self‐reported measures (e.g. participant diaries)</p> </li> <li> <p>secondary count measures (e.g. pill counting, days of intravenous antibiotics)</p> </li> <li> <p>electronic data (e.g. downloaded nebuliser data)</p> </li> </ol> </li> <li> <p>Adverse effects of treatment</p> <ol id="CD012300-list-0007"> <li> <p>mild (self‐limiting, not requiring treatment change, e.g. wheeze with inhaled therapy which settles </p> </li> <li> <p>moderate (requires treatment discontinuation, e.g. ototoxicity (damage to the ears causing hearing loss or balance problems)) </p> </li> <li> <p>severe (e.g. hospitalisation or death)</p> </li> </ol> </li> <li> <p>Mortality</p> </li> <li> <p>Isolation of resistant bacteria (with detection method, i.e. conventional culture or molecular techniques, described where possible) </p> <ol id="CD012300-list-0008"> <li> <p>PA with a new resistance pattern</p> </li> <li> <p>methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) </p> </li> <li> <p>resistant gram negative organisms (e.g. <i>Stenotrophomonas maltophilia</i> , <i>Burkholderia cepacia</i> , <i>Achromobacter xylosoxidans</i>) </p> </li> <li> <p>other novel organisms</p> </li> </ol> </li> <li> <p>Cost effectiveness</p> </li> </ol> </p> </section> </section> </section> <section id="CD012300-sec-0040"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD012300-sec-0041"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Cystic Fibrosis and Genetic Disorders Group's Information Specialist conducted a search of the Group's Cystic Fibrosis Trials Register for relevant trials using the following terms: (pseudomonas aeruginosa OR mixed infections) AND (eradication OR preventative OR unknown).<br/> <br/> The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of most recent search: 28 October 2019.</p> <p>We also searched the following trial registries:</p> <p> <ul id="CD012300-list-0009"> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>; searched 21 August 2019); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 21 August 2019); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>; searched 21 August 2019). </p> </li> </ul> </p> <p>For details of our search strategies, please see the appendices (<a href="./appendices#CD012300-sec-0122">Appendix 1</a>). </p> </section> <section id="CD012300-sec-0042"> <h4 class="title">Searching other resources</h4> <p>Two review authors (SP and SS) checked the bibliographies of all included trials and any relevant systematic reviews identified for further references to relevant trials. The review authors contacted the chief investigator of any included trials for unpublished data. </p> </section> </section> <section id="CD012300-sec-0043"> <h3 class="title" id="CD012300-sec-0043">Data collection and analysis</h3> <p>Where the review authors were unable to use all the analysis methods described below due to insufficient trials they plan to do so in future should sufficient trials be identified. </p> <section id="CD012300-sec-0044"> <h4 class="title">Selection of studies</h4> <p>One review author (SP) screened the titles and abstracts of identified trials for inclusion in this review according to the processes set out in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012300-bbs2-0054" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>); one of two further authors (AA or SS) then also screened these references. The authors excluded trials which were obviously irrelevant and removed duplicates. No trials identified required translation into English, but the authors planned to arrange this if required. </p> <p>Two authors (SP and SS) independently screened the identified trials against the review's eligibility criteria and collated multiple reports of the same trial where necessary. They were not blinded to the trial authors. They resolved any disagreement by discussion and in consultation with a third author (AS) where necessary. They contacted the corresponding trial investigator(s) for further information where it was necessary to decide whether to include a trial in the review. </p> </section> <section id="CD012300-sec-0045"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SS and SP) independently extracted data using a data collection form which was agreed by all review authors. The data collection form included information on the trial authors and eligibility, in addition to the trial methods (type of trial, blinding, setting, duration, number of centres and dropouts) and outcome data. For each trial the review authors documented the length of time after first isolation of PA that a participant could be randomised and also the length of time after successful eradication that a participant could be randomised. They additionally recorded the active intervention (antibiotic type, route of administration, dose, duration) and the control intervention. They considered all antibiotic regimens together; if they had identified sufficient trials, they would have undertaken a subgroup analysis of administration route. They collected data on the participant demographics, including information on participants who dropped out. </p> <p>The review authors collected data from the text, tables and online supplements where appropriate and resolved any disagreements by discussion. Only a subset of participants from the included trial were eligible for inclusion in this review, so the review authors requested individual participant data (IPD) from the trial authors and one author (SP) analysed these using Microsoft Excel (<a href="./references#CD012300-bbs2-0074" title="Microsoft Corporation. MS Excel. Washington, USA: Microsoft Corporation, 2016. ">MS Excel 2016</a>) and Stata version 16 (<a href="./references#CD012300-bbs2-0099" title="StataCorp LLC. Stata Statistical Software: Release 16. Version 16. College Station, Texas, USA: StataCorp LLC, 2019. ">Stata 2019</a>) to determine the baseline characteristics of the subset of participants eligible for inclusion and their outcome data. </p> <p>The authors planned to present data at two weeks, one month, three months, six months and one and two years. For the included trial we have reported the time points 'up to three months', 'up to six months', 'up to one year' and 'up to two years' and entered the data into the Review Manager software (<a href="./references#CD012300-bbs2-0087" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD012300-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (SP and SS) independently assessed the included trial for any risks of bias using the Cochrane's Risk of Bias tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012300-bbs2-0055" title="HigginsJP , AltmanDG , Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This tool facilitates the identification of bias in the following domains: </p> <p> <ul id="CD012300-list-0010"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective reporting;</p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>We classified each domain as having a high, low or unclear risk of bias. We resolved any disagreement by discussion and sought the opinion of a third author (AS) where necessary. </p> </section> <section id="CD012300-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, such as mortality, development of resistant bacteria and adverse events, the review authors sought data on the number of participants with each outcome and by allocated treatment group. We planned to conduct an intention‐to‐treat analysis. Data were available to conduct an intention‐to‐treat analysis for number of participants with a pulmonary exacerbation, severe adverse events and development of resistant organisms. Adherence was calculated from returned medication so an available‐case analysis was carried out for this outcome. We calculated the risk of the outcome in treatment group compared to the risk of the outcome in the control group (pooled risk ratio (RR) and its 95% confidence interval (CI)). </p> <p>For continuous data, such as change in QoL scores, pulmonary function tests and nutritional parameters, the review authors calculated the pooled mean difference (MD) and its 95% CI between the intervention and control groups. If in the future different trials use different scales, they planned to calculate the pooled standardised mean difference (SMD). The authors planned to report skewed data narratively. </p> <p>The review authors analysed common count data (such as number of days in hospital) as continuous data, as described in the<i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD012300-bbs2-0045" title="DeeksJJ , HigginsJP , Altman DG on behalf of the CSMG, editor(s) . Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>For time‐to‐event data (such as time to next isolation of PA) the review authors calculated the pooled hazard ratios (HRs) and their 95% CIs using the Cox Proportional Hazards model in Stata version 16 (<a href="./references#CD012300-bbs2-0099" title="StataCorp LLC. Stata Statistical Software: Release 16. Version 16. College Station, Texas, USA: StataCorp LLC, 2019. ">Stata 2019</a>). They then created forest plots using the generic inverse variance method in RevMan (<a href="./references#CD012300-bbs2-0087" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD012300-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>The review authors have not included any cross‐over trials* as this is an inappropriate design for the review question. It is firstly unlikely that all participants would have fulfilled the primary outcome (time until a new growth of PA) at the point of cross‐over; and secondly, once the outcome was reached cross‐over would be meaningless. Cluster‐randomised trials* are also inappropriate as there may be geographical differences between the PA strains which could affect eradication and re‐acquisition rates. The review authors planned to analyse factorial trials, where there was no suggestion of an interaction between the two interventions, separately (<a href="./references#CD012300-bbs2-0056" title="HigginsJP , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s) . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). If we had included a trial which compared multiple treatment arms of interest we would have presented these in separate comparisons. We planned to directly compare treatments of differing durations as each represents a separate treatment regimen. </p> <p>* For definitions of these types of trial please see the Cochrane online glossary (<a href="https://community-archive.cochrane.org/glossary" target="_blank">community‐archive.cochrane.org/glossary</a>). </p> </section> <section id="CD012300-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>The review authors contacted the trial authors for missing data and received IPD for all the trial participants who had consented to data sharing. We then extracted the data for the relevant subset of participants for analysis. We attempted to collect data on the number of participants with each outcome according to the allocated group, allowing an intention‐to‐treat analysis. Where necessary, the authors planned to use the methods described in chapter 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to impute these data (<a href="./references#CD012300-bbs2-0054" title="HigginsJP , DeeksJJ , editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). If we had needed to impute significant amounts of data, we would have undertaken a sensitivity analysis to compare the effects of the imputed data against the available case data. </p> <p>For the included trial the review authors analysed the primary outcome measure on an intention‐to‐treat analysis, including all the participants who met the review's inclusion criteria. This was also possible for 'time to next pulmonary exacerbation', 'adverse effects', and 'isolation of resistant pathogens'. For each time point the authors presented an available‐case analysis, including all participants for whom data were available at that time point. </p> </section> <section id="CD012300-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>Had there been sufficient trials to undertake a meta‐analysis, the review authors planned to test for heterogeneity using the I² statistic, and interpret this according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012300-bbs2-0045" title="DeeksJJ , HigginsJP , Altman DG on behalf of the CSMG, editor(s) . Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We note that the usefulness of I² depends on the magnitude and direction of the intervention effects and the strength of the evidence of heterogeneity. We would have considered an I² value of 0% to 30% to represent little or no heterogeneity, 30% to 50% to represent moderate heterogeneity, 50% to 75% to represent substantial heterogeneity and above 75% to represent considerable heterogeneity. </p> </section> <section id="CD012300-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>The review authors aimed to minimise the effects of reporting biases through a number of strategies. We assessed publication bias by a comprehensive search of grey literature and clinical trials databases, as well as by discussion with researchers in the field in an attempt to identify unpublished data; this would also have helped reduce location and citation bias. We are, however, aware of the potential bias inherent in the inclusion of unpublished data. The eligibility of inclusion of trials published in any language reduced the risk of language and location bias. The review authors carefully screened trials at inclusion to look for evidence of duplicate publication, including author names, sites, interventions and participant characteristics. </p> <p>We assessed outcome reporting bias by comparing outcomes specified in the 'Methods' section to those reported in the results of the full trial paper. We further investigated this bias by comparing the outcomes reported in the full paper to those stated in the published protocol (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). We further compared the stated outcomes to those published on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>. Had any further concerns remained we planned to contact the trial authors to request the original trial protocol. </p> <p>Had the review authors identified a sufficient number of trials (i.e. at least 10), we planned to construct funnel plots comparing trial effect to trial size. We planned to visually inspect these plots for evidence of asymmetry and, where appropriate, test for asymmetry as discussed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012300-bbs2-0100" title="SterneJA , EggerM , Moher D on behalf of the Cochrane Bias Methods Group, editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 updated March 2011. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). We are aware that other causes of asymmetry in a funnel plot are possible and would have considered the impact of these other factors. </p> </section> <section id="CD012300-sec-0052"> <h4 class="title">Data synthesis</h4> <p>If the review authors had been able to combine sufficient trials, we planned to assess the extracted data using a fixed‐effect meta‐analysis. In the case of substantial heterogeneity (I² greater than 50%), we would have conducted a random‐effects meta‐analysis. We present the data from the single included trial using a fixed‐effect analysis. </p> </section> <section id="CD012300-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The review authors planned to undertake the following subgroup analyses as appropriate:</p> <p> <ul id="CD012300-list-0011"> <li> <p>comparison of the effect of route of antibiotic administration (oral versus inhaled versus intravenous); </p> </li> <li> <p>comparison between participants who underwent eradication of a first episode of PA infection versus those with previous PA infection; </p> </li> <li> <p>comparison of differing methods of PA detection;</p> </li> <li> <p>comparison of differing definitions of recurrent PA infection;</p> </li> <li> <p>comparison of differing definitions of chronic PA infection.</p> </li> </ul> </p> </section> <section id="CD012300-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>If appropriate the review authors would have undertaken a sensitivity analysis to ascertain whether the results of the review are robust. We would have excluded trials assessed as having a high risk of bias (more than 50% of domains with a high risk) and would have repeated the analysis to see if this has any effect on the results. If the sensitivity analysis had shown little difference, there would have been greater confidence in the results. Furthermore, in situations where the authors had made arbitrary decisions, such as the time points for analysis, or if we had imputed significant amounts of data, we would have carried out a sensitivity analysis to assess the impact of these decisions. Once again similar results would have strengthened the conclusions of this review, while conversely a marked difference would mean the review results would need to be interpreted more cautiously. </p> <p>A sensitivity analysis was carried out to ascertain whether the authors decision to define eradication in the included trial as PA culture negativity at visit 2 had any effect on the primary outcome. </p> <section id="CD012300-sec-0055"> <h5 class="title">Summary of findings table</h5> <p>The review authors constructed a summary of findings table for the single comparison in the review, cycled therapy versus culture‐based therapy. They considered the following outcomes: </p> <p> <ol id="CD012300-list-0012"> <li> <p>time to next isolation of PA;</p> </li> <li> <p>QoL;</p> </li> <li> <p>FEV<sub>1</sub> (change from baseline); </p> </li> <li> <p>frequency of pulmonary exacerbations;</p> </li> <li> <p>time to chronic PA infection;</p> </li> <li> <p>adverse events; and</p> </li> <li> <p>emergence of novel bacteria.</p> </li> </ol> </p> <p>We used the GRADE approach, described in chapter 12 of <i>the Cochrane Handbook of Systematic Review for Interventions</i> (<a href="./references#CD012300-bbs2-0094" title="SchünemannHJ , OxmanAD , VistGE , HigginsJP , DeeksJJ , GlasziouP , et al on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) to classify the body of evidence for each outcome as high, moderate, low or very low. We downgraded the quality of the evidence across five domains; risk of bias, indirectness, inconsistency, imprecision and publication bias. Where there was serious risk of bias we downgraded by one level and where it was very serious we downgraded it by two levels. Where we judged the evidence not to be high quality, we described the rationale for this judgement in footnotes to the table. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012300-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012300-sec-0056"></div> <section id="CD012300-sec-0057"> <h3 class="title">Description of studies</h3> <p>Please see the tables for the characteristics of the included trials (<a href="./references#CD012300-sec-0130" title="">Characteristics of included studies</a>; <a href="./references#CD012300-sec-0131" title="">Characteristics of excluded studies</a>; <a href="./references#CD012300-sec-0132" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD012300-sec-0133" title="">Characteristics of ongoing studies</a>). </p> <section id="CD012300-sec-0058"> <h4 class="title">Results of the search</h4> <p>The results of the searches are presented in a PRISMA diagram (<a href="#CD012300-fig-0001">Figure 1</a>). We identified 371 unique references to 155 trials from electronic searches and one further trial was identified following discussion with the lead author of another trial. No further trials were identified from searches of other trial databases or the reference lists of other trials. </p> <div class="figure" id="CD012300-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012300-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Following review of title and abstract, we excluded 124 trials and obtained the full texts for the remaining 31 trials. One trial was included for analysis (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>) and one trial is ongoing (<a href="./references#CD012300-bbs2-0031" title="EUCTR2011‐000801‐39‐SE . Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosis [www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐000801‐39‐SE]. (first received 13 December 2011). [CFGD Register: PI252c] KollbergH , LarssonA , NilssonE . Anti‐pseudomonas IGY ready for phase III. Pediatric Pulmonology2010;45 Suppl 33:343. [Abstract no.: 345; CENTRAL: 848799; CFGD Register: PI252a; CRS: 5500100000003664] LarssonA . Phase III study (IMPACTT) on anti‐pseudomonas IgY. Journal of Cystic Fibrosis2011;10 Suppl 1:S24. [Abstract no.: 92; CENTRAL: 848800; CFGD Register: PI252b; CRS: 5500100000003666] NCT01455675 . Efficacy study of igy (antibody against pseudomonas) in cystic fibrosis patients [Phase III study to evaluate clinical efficacy and safety of avian polyclonal anti‐pseudomonas antibodies (igy) in prevention of recurrence of pseudomonas aeruginosa infection in cystic fibrosis patients]. clinicaltrials.gov/show/nct01455675 (first received 2011 October 20). [CENTRAL: CN‐01533433; CFGD Register: PE252e; CRS: 8286130] SchusterA , BendJ , HoibyN , VerdePE , RottmannA , LarssonA , et al. Clinical study to evaluate an anti‐Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011‐000801‐39). Journal of Cystic Fibrosis2019;18:S23. [Abstract no.: WS12‐5; CENTRAL: CN‐01990653; CFGD Register: PI252d; CRS: 12181829; EMBASE: 2001976053] ">Larsson 2011</a>). The trial identified through discussion with the lead author is listed as 'Awaiting classification' since only a subset of participants for this trial will be eligible for inclusion; IPD have been requested, but are not available at this time (<a href="./references#CD012300-bbs2-0030" title="Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early Pseudomonas infection in cystic fibrosis: the Optimize randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177‐87. [CFGD Register: MA31b; DOI: 10.1164/rccm.201802‐0215OC; PUBMED: 29890086] Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial [Erratum: Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial (American Journal of Respiratory and Critical Care Medicine (2018) 198 (1177–1187) DOI: 10.1164/rccm.201802‐0215OC)]. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CENTRAL: CN‐01967101; CFGD REgister: MA31d; CRS: 11932900; DOI: 10.1164/rccm.201802‐0215OC; EMBASE: 2001700512; PUBMED: 30874457] NCT02054156 . Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis [Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis: the OPTIMIZE multicenter, placebo‐controlled, double‐blind, randomized trial]. clinicaltrials.gov/show/NCT02054156 (first received 2014 February 04). [CENTRAL: CN‐01543461; CFGD Register: MA31c; CRS: 8295539] RamseyBW , Retsch‐BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52 Suppl 47:380‐1. [Abstract no. : 434; CFGD Register: MA31a] ">OPTIMIZE 2018</a>). The remaining 28 trials were excluded with reasons (<a href="./references#CD012300-sec-0131" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD012300-sec-0059"> <h4 class="title">Included studies</h4> <p>One trial has been identified for inclusion in this review (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <section id="CD012300-sec-0060"> <h5 class="title">Trial design</h5> <p>The trial is a factorial design primarily looking at strategies to eradicate PA (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). It was randomised 1:1:1:1 to each of four treatment regimens. Culture‐based therapy versus cycled therapy was open label, but the addition of ciprofloxacin or placebo to the tobramycin solution (TIS) regimen was blinded; outcomes assessors were blinded to all treatment allocation. This was a multicentre trial conducted at 55 CF centres in the USA. The planned duration of follow‐up was 18 months, which was achieved. </p> </section> <section id="CD012300-sec-0061"> <h5 class="title">Participants</h5> <p>Investigators randomised 306 participants (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>); 304 were included in the trial intention‐to‐treat analysis as two participants were subsequently found to have failed screening. The gender split was approximately equal; 154 participants were female (150 male). The trial did not include adults or adolescents; eligible participants were aged one to 12 years (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Participants had to have had either a lifetime first isolation of PA or a new isolation, defined as at least a two‐year absence of PA having had at least one respiratory culture examined per year. Participants could have had their PA positive sample up to six months prior to enrolment and have had up to one course of anti‐pseudomonal antibiotic therapy in that time (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <p>The trial did not require specific evidence of eradication prior to commencement of the treatment regimen. For the purposes of this review only participants with documented eradication were eligible; participants with a positive PA sample at visit 2 (approximately three weeks after commencement of the initial course of therapy) were therefore excluded. </p> <p>There were no significant differences between the groups in any of the baseline parameters for our included subset of 253 participants (124 males and 129 females). In the cycled‐therapy group 59 out of 119 (49.6%) were female and in the culture‐based therapy group 70 out of 134 (52.2%) were female. The mean age in the cycled group was 6.0 years and in the culture‐based group was 5.6 years. Baseline weight was 21.5 kg in the cycled group and 20.3 kg in the culture‐based group; baseline height was 111.0 cm in the cycled group versus 107.9 cm in the culture‐based group. Baseline FEV<sub>1</sub> was 1.53 L in the cycled group and 1.51 L in the culture‐based group. No data on the individual mutations were available. </p> </section> <section id="CD012300-sec-0062"> <h5 class="title">Interventions</h5> <p>All participants underwent an initial course of inhaled TIS 300 mg twice daily for 28 days. This could be extended for a further 28 days if samples taken at the week 3 visit remained positive for PA. </p> <p>The trial compared two separate interventions in a factorial design. The first comparison was cycled therapy, in which participants received TIS 300 mg twice daily every three months regardless of culture results, compared to culture‐based therapy, in which participants received TIS 300 mg twice daily only in the three‐month periods in which their respiratory samples were positive for PA. The second comparison was between the addition of oral ciprofloxacin 15 to 20 mg/kg/dose (up to 750 mg) twice daily for 14 days with every TIS cycle versus matched placebo. Participants were therefore randomised to one of four groups: cycled therapy and ciprofloxacin; or cycled therapy and placebo; or culture‐based therapy and ciprofloxacin; or culture‐based therapy and placebo (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). For this review only the cycled versus culture‐based comparison was eligible. </p> </section> <section id="CD012300-sec-0063"> <h5 class="title">Outcomes</h5> <p>The primary outcome was the time to next pulmonary exacerbation, which was defined a priori as a pulmonary exacerbation requiring either intravenous antibiotics or hospitalisation; less severe pulmonary exacerbations were a secondary endpoint. This trial also had a primary microbiological endpoint, the proportion of respiratory samples which were positive for PA at each three‐month time‐point after the first treatment cycle (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Further secondary endpoints were safety (monitored by adverse events and audiology), changes in height, weight and lung function, additional safety measures including musculoskeletal symptoms, haematological, liver and renal profiles and the emergence of resistant PA or other new pathogens (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded 28 trials from the review. Nine trials assessed participants with chronic PA infection (<a href="./references#CD012300-bbs2-0003" title="CarswellF , WardC , CookDA , SpellerDC . A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. British Journal of Diseases of the Chest1987;81(4):356‐60. [CENTRAL: 53621; CFGD Register: PI54; CRS: 5500100000000343; PUBMED: 3329531] ">Carswell 1987</a>; <a href="./references#CD012300-bbs2-0005" title="ConwaySP , MillerMG , RamsdenC , LittlewoodJM . Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatrica Scandinavica1985;74(1):107‐13. [CENTRAL: 37577; CFGD Register: PI34b; CRS: 5500100000000223; PUBMED: 3885674] ConwaySP , MillerMG , RamsdenCH , LittlewoodJM . Comparison of netilmicin‐plus ticarcillin and tobramycin plus ticarcillin in exacerbations of pseudomonas chest infection in cystic fibrosis. 12th Annual Meeting European Working Group for Cystic Fibrosis; 1983 Oct; Athens, Greece. 1983:271. [CENTRAL: 291257; CFGD Register: PI34a; CRS: 5500100000001322] ">Conway 1985</a>; <a href="./references#CD012300-bbs2-0006" title="DayAJ , WilliamsJ , McKeownC , BrutonA , WellerPH . Evaluation of inhaled colomycin in children with cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series1988;74:R(c)3. [CENTRAL: 291275; CFGD Register: PI85; CRS: 5500100000001339] ">Day 1988</a>; <a href="./references#CD012300-bbs2-0007" title="DinwiddieR , HindmarshP , LockP . Azlocillin compared to gentamicin in the treatment of pseudomonas infection in cystic fibrosis. 11th European Cystic Fibrosis Conference; 1982; Brussels. 1982:229. [CENTRAL: 291277; CFGD Register: PI123; CRS: 5500100000001341] ">Dinwiddie 1982</a>; <a href="./references#CD012300-bbs2-0018" title="Cystic Fibrosis Foundation. Inhaled ciprofloxacin. www.cff.org (www.cff.org/clinicaltrials) (accessed 17 February 2010). [CENTRAL: 744141; CFGD Register: PI261c; CRS: 5500100000003467] DorkinH , CriolloM , ReimnitzP , AlderJ , HampelB . Randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis‐ a phase IIB study of ciprofloxacin dry powder for inhalation (DPI). Pediatric Pulmonology2011;46 Suppl 34:296. [Abstract no.: 235; CFGD Register: PI261a] NCT00645788 . Study to evaluate the safety and efficacy of ciprofloxacin (inhaled) in patients with cystic fibrosis [Randomized, double‐blind, placebo‐controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis]. clinicaltrials.gov/show/NCT00645788 (first posted 28 March 2008). [CENTRAL: 744140; CFGD Register: PI261b; CRS: 5500100000003466] ">NCT00645788</a>; <a href="./references#CD012300-bbs2-0019" title="FlumeP , VanDevanterDR , CohenF , FlemingR , ElbornJS . Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials. Journal of Cystic Fibrosis2015;14 Suppl 1:S87. [Abstract no.: 117; CENTRAL: 1077213; CFGD Register: PI240f // PI283c // PI284c ; CRS: 5500135000001302] FlumePA , VanDevanterDR , MorganEE , DudleyMN , LoutitJS , BellSC , et al. A phase 3, multi‐center, multinational, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT‐1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis2016;15(4):495‐502. [CFGD Register: PI284d; CRS: 5500135000001727; PUBMED: 26852040] FlumePA , VanDevanterDR , MorganEE , DudleyMN , LoutitJS , BellSC , et al. A phase 3, multi‐center, multinational, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT‐1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society2016;15(4):495‐502. Online supplement. [CFGD Register: PI284e; CRS: 5500135000001734] NCT01180634 . MP‐376 (Aeroquin™, Levofloxacin for Inhalation) in patients with cystic fibrosis [A phase 3, multi‐center, multinational, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of MP‐376 (Levofloxacin Inhalation Solution; Aeroquin™) in stable cystic fibrosis patients]. clinicaltrials.gov/show/NCT01180634 (first posted 12 August 2010). [CENTRAL: 1012532; CFGD Register: PI284a; CRS: 5500131000000190] VanDevanterD , FlumePA , FlemingR , ElbornJ . How often is pulmonary exacerbation defined by ≥4 Fuchs criteria associated with antibiotic treatment?. Pediatric Pulmonology2014;49 Suppl 38:356. [Abstract no.: 388; CENTRAL: 1012531; CFGD Register: PI283b // PI284b ; CRS: 5500131000000188] ">NCT01180634</a>; <a href="./references#CD012300-bbs2-0013" title="ChironR , GellerDE , AngyalosiG , DebonnettL , YadaoA , BaderG , et al. Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial. Journal of Cystic Fibrosis2014;13 Suppl 2:S57. [Abstract no.: 42; CENTRAL: 996576; CFGD Register: PI239k; CRS: 5500129000000011] GellerDE , FlumePA , BrockhausF , ZhangJ , AngyalosiG , HeE , et al. Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2010;9 Suppl 1:S22. [Abstract no.: 82; CENTRAL: 776791; CFGD Register: PI239b; CRS: 5500100000003511] GellerDE , FlumePA , KonstanM , AngyalosiG , HigginsM . Microbiological and clinical response to tobramycin inhalation powder (TIP™) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection. Journal of Cystic Fibrosis2011;10 Suppl 1:S21. [Abstract no.: 82; CENTRAL: 848918; CFGD Register: PI239g; CRS: 5500100000010633] GellerDE , NasrSZ , PiggottS , HeE , AngyalosiG , HigginsM . Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Respiratory Care2014;59(3):388‐98. [CFGD Register: PI239l; CRS: 5500135000000283; PUBMED: 23983274] KonstanM , FlumePA , BrockhausF , AngyalosiG , He , E , et al. Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa). Journal of Cystic Fibrosis2010;9 Suppl 1:S22. [Abstract no.: 82; CENTRAL: 776166; CFGD Register: PI239a; CRS: 5500100000003510] KonstanMW , FlumePA , BrockhausF , AngyalosiG , HeE , ZhangJ , et al. Tobramycin inhalation powder (TIP) versus tobramycin inhalation solution (TOBI®): the EAGER trial. Pediatric Pulmonology2010;45 Suppl 33:303. [Abstract no.: 235; CENTRAL: 848925; CFGD Register: PI239c; CRS: 5500100000010710] KonstanMW , FlumePA , KapplerM , ChironR , HigginsM , BrockhausF , et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis2011;10(1):54‐61. [CENTRAL: 779828; CFGD Register: PI239e; CRS: 5500100000005985] NasrS , NickJ , EzzetN , GalloP , DebonnettL , AngyalosiG , et al. Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial. Pediatric Pulmonology2013;48 Suppl 36:283. [Abstract no.: 219; CENTRAL: 921693; CFGD Register: PI239j; CRS: 5500125000000404] RegnaultA , BalpMM , KulichK , EsteveL , VialaDM . Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis. Journal of Cystic Fibrosis2011;10 Suppl 1:S85. [Abstract no.: 332; CENTRAL: 848877; CFGD Register: PI239f; CRS: 5500100000010559] RegnaultA , BalpMM , KulichK , EsteveL , Viala‐DantenM . Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study. Journal of Cystic Fibrosis2011;10 Suppl 1:S82. [Abstract no.: 323; CENTRAL: 848926; CFGD Register: PI239d; CRS: 5500100000010711] RegnaultA , BalpMM , KulichK , Viala‐DantenM . Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis. Journal of Cystic Fibrosis2012;11(6):494‐501. [CENTRAL: 867326; CFGD Register: PI239i; CRS: 5500100000011297; PUBMED: 22583743] ">Konstan 2011a</a>; <a href="./references#CD012300-bbs2-0017" title="AnbarRD , YuX , ColinAA . Reduction of pulmonary hospitalizations during a randomized, controlled, open‐label study of tobramycin solution for inhalation in young CF patients with mild lung disease. Pediatric Pulmonology2003;Suppl 25:296. [CENTRAL: 451881; CFGD Register: PI175b; CRS: 5500100000002383] ColinAA , AnbarRD , YuX . Reduction in pulmonary hospitalizations during a randomized, controlled, open‐label study of tobramycin solution for inhalation in young CF patients with mild lung disease. Journal of Cystic Fibrosis2003;2 Suppl 1:S22. [CENTRAL: 431305; CFGD Register: PI175a; CRS: 5500100000002302] MurphyTD , AnbarRD , LesterLA , NasrSZ , NickersonB , VanDevanterDR , et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatric Pulmonology2004;38(4):314‐20. [CENTRAL: 496874; CFGD Register: PI175c; CRS: 5500100000002652; EMBASE: 2004402409; PUBMED: 15334509] ">Murphy 2004</a>; <a href="./references#CD012300-bbs2-0021" title="BirnbaumHG , GreenbergP , FinkelsteinS , BerndtE , OttoKL , MontgomeryAB , et al. Economic analysis of hospitalization and home IV anti‐pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI®). Pediatric Pulmonology1998;Suppl 17:273. [CENTRAL: 792738; CFGD Register: PI120f; CRS: 5500100000003553] BowmanCM . The long‐term use of inhaled tobramycin in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1 Suppl 2:S194‐8. [CENTRAL: 451888; CFGD Register: PI120cc; CRS: 5500100000002389; PUBMED: 15463834] BurnsJL , VanDalfsenJM , ShawarRM , OttoKL , GarberRL , QuanJM , et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Journal of Infectious Diseases1999;179(5):1190‐6. [CENTRAL: 161606; CFGD Register: PI120i; CRS: 5500100000000895; PUBMED: 10191222] CaseyS , RamseyB , BorowitzD . Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents. 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:172. [CENTRAL: 302945; CFGD Register: PI120ff; CRS: 5500100000001685] EngerC , RothmanK , KylstraJW . Mortality rates during 2 years of treatment with intermittent inhaled tobramycin (TOBI) in CF. Pediatric Pulmonology1999;Suppl 19:339‐40. [CENTRAL: 291292; CFGD Register: PI120m; CRS: 5500100000001353] FielS , VanDevanterD , YuX . Effect of tobramycin solution for inhalation on pulmonary function decline rates in exacerbating and stable CF patients. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P195. [CENTRAL: 354406; CFGD Register: PI120s; CRS: 5500100000001933] FielSB . Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients. European Respiratory Journal2000;16 Suppl 31:1545. [CENTRAL: 415647; CFGD Register: PI120dd; CRS: 5500100000002265] GellerDE , PitlickWH , NardellaPA , TracewellWG , RamseyBW . Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest2002;122(1):219‐26. [CENTRAL: 404033; CFGD Register: PI120bb; CRS: 5500100000002214] GraffGR , GordonDC , VanDalfsenJM , BurnsJL . Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI®) study. Pediatric Pulmonology2000;Suppl 20:283. [CENTRAL: 793580; CFGD Register: PI120p; CRS: 5500100000003564] HazinskiTA . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Journal of Pediatrics1999;135(1):130. [CENTRAL: 165714; CFGD Register: PI120j; CRS: 5500100000000909; EMBASE: 1999019576; PUBMED: 10428654] KonstanMW , VanDevanterDR . Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis. Pediatric Pulmonology2001;Suppl 22:305. [CENTRAL: 362193; CFGD Register: PI120v; CRS: 5500100000001991] KylstraJW , BowmanCM , MeyerU , MontgomeryAB , SchaefflerB , StewartP , et al. Who benefits more? An age‐stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin. Netherlands Journal of Medicine1999;54 Suppl:S83. [CENTRAL: 291415; CFGD Register: PI120k; CRS: 5500100000001449] LeLorierJ , PerreaultS , BirnbaumH , GreenbergP , SheehyO . Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clinical Therapeutics2000;22(1):140‐51. [CENTRAL: 275378; CFGD Register: PI120o; CRS: 5500100000001232; PUBMED: 10688397] LiPumaJJ . Microbiological and immunologic considerations with aerosolized drug delivery. Chest2001;120(3 Suppl):118S‐23S. [CENTRAL: 356379; CFGD Register: PI120x; CRS: 5500100000001971; PUBMED: 11555566] MacLeodDL , NelsonLE , ShawarRM , LinBB , LockwoodLG , DirkJE , et al. Aminoglycoside‐resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long‐term, intermittent, inhaled tobramycin treatment. Journal of Infectious Diseases2000;181(3):1180‐4. [CENTRAL: 302968; CFGD Register: PI120n; CRS: 5500100000001702] MossR , KylstraJW , MontgomeryAB , GibsonR . Who benefits more? An analysis of FEV1 and weight in adolescent (age 13‐&lt;18) CF patients using inhaled tobramycin (TOBI). Pediatric Pulmonology1999;Suppl 19:243. [CENTRAL: 291469; CFGD Register: PI120k; CRS: 5500100000001497] MossRB . Administration of aerosolized antibiotics in cystic fibrosis patients. Chest2001;120(3 Suppl):107S‐13S. [CENTRAL: 368291; CFGD Register: PI120y; CRS: 5500100000002023] MossRB . Long‐term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest2002;121(1):55‐63. [CENTRAL: 377132; CFGD Register: PI120aa; CRS: 5500100000002049; PUBMED: 11796432] NickersonB , MontgomeryAB , KylstraJW , RamseyBW . Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients. Pediatric Pulmonology1999;Suppl 19:243‐4. [CENTRAL: 291479; CFGD Register: PI120l; CRS: 5500100000001506] OttoKL , MontgomeryAB , LinA , RamseyBW . Seasonality of hospitalization for pulmonary exacerbations and lower respiratory tract infections in Phase III tobramycin solution for inhalation (TOBI®) trials. Pediatric Pulmonology1998;Suppl 17:273. [CENTRAL: 795752; CFGD Register: PI120e; CRS: 5500100000003601] QuanJM , VasiljevM , SchaefflerB , PhelpsC , BurringtonC , MeyerU . Treatment for exacerbation only does not arrest progressive lung function decline in CF. Netherlands Journal of Medicine1999;54 Suppl:S84. [CENTRAL: 291523; CFGD Register: PI120g; CRS: 5500100000001545] QuittnerA , GordonD , YuX . Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P326. [CENTRAL: 614345; CFGD Register: PI120t; CRS: 5500100000003153] QuittnerAL , BuuA . Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology2002;33(4):269‐76. [CENTRAL: 379174; CFGD Register: PI120z; CRS: 5500100000002059; PUBMED: 11921456] QuittnerAL , BuuA , GordonD . Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials. Pediatric Pulmonology2001;Suppl 22:349. [CENTRAL: 362214; CFGD Register: PI120w; CRS: 5500100000002002] RamseyB , BurnsJ , SmithA . Safety and efficacy of Tobramycin Solution for Inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials. Pediatric Pulmonology1997;Suppl 14:137‐8. [CENTRAL: 385760; CFGD Register: PI120c; CRS: 5500100000002121] RamseyBW , BowmanMC , MontgomeryAB , SmithAR , TOBI Study Group. Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy. 21st European Cystic Fibrosis Conference; 1997 Jun 1‐6; Davos, Switzerland. 1997:144. [CENTRAL: 291527; CFGD Register: PI120b; CRS: 5500100000001548] RamseyBW , BowmanMC , Vasiljev‐KM , SmithAR , TOBI Study Group. Results of phase 3 aerosolized tobramycin studies for chronic intermittent therapy. 21st European Cystic Fibrosis Conference; 1997 Jun 1‐6; Davos, Switzerland. 1997:144. [CENTRAL: 291528; CFGD Register: PI120a; CRS: 5500100000001549] RamseyBW , PepeMS , QuanJM , OttoKL , MontgomeryAB , Williams WarrenJ , et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine1999;340(1):23‐30. [CENTRAL: 158508; CFGD Register: PI120d; CRS: 5500100000000883; PUBMED: 9878641] RosenfeldM , EmersonJ , Williams‐WarrenJ , PepeM , SmithA , MontgomeryAB , et al. Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics2001;139(3):359‐65. [CENTRAL: 384105; CFGD Register: PI120ee; CRS: 5500100000002077; PUBMED: 11562614] TaylorCJ . Nebulised high dose Tobramycin (TOBI) in adolescents with cystic fibrosis. Pediatric Pulmonology2001;Suppl 22:291. [CENTRAL: 362226; CFGD Register: PI120u; CRS: 5500100000002008] VanDevanterD , HouK , YuX . Effect of tobramycin solution for inhalation (TOBI®) on long term rates of lung function decline in Pseudomonas aeruginosa infected cystic fibrosis (CF) patients with mild to moderate lung disease. Pediatric Pulmonology2000;Suppl 20:298. [CENTRAL: 793150; CFGD Register: PI120q; CRS: 5500100000003557] VanDevanterD , YuX , KonstanMW . Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P172. [CENTRAL: 354463; CFGD Register: PI120r; CRS: 5500100000001964] ">Ramsey 1999</a>). In two trials participants were PA negative at baseline (<a href="./references#CD012300-bbs2-0004" title="ConnettGJ , PikeKC , LeggJP , CathieK , DewarA , FooteK , et al. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study. Therapeutic Advances in Respiratory Disease2015;9(6):272‐80. [CFGD Register: PI282b] LeggJ , PikeK , CathieK , DewarA , FooteK , HarrisA , et al. A randomized double‐blind, placebo‐controlled trial of ciprofloxacin in the treatment of upper respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonlogy2014;49 Suppl 38:333. [Abstract no.: 325; CFGD Register: PI282a] ">Connett 2015</a>; <a href="./references#CD012300-bbs2-0009" title="FrederiksenB , KochC , HoibyN , PresslerT , HansenA . Effect of aerosolised rhDnase (Pulmozyme®) on pulmonary infections in CF: an open randomised study. Pediatric Pulmonology2000;Suppl 20:246. [CENTRAL: 792917; CFGD Register: BD97a; CRS: 5500100000003555] FrederiksenB , PresslerT , HansenA , KochC , HoibyN . Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatrica2006;95(9):1070‐4. [CENTRAL: 571885; CFGD Register: BD97b; CRS: 5500100000002869; EMBASE: 2006449673; PUBMED: 16938752] ">Frederiksen 2006</a>). Four trials compared short‐term antibiotic strategies for treating acute pulmonary exacerbations (<a href="./references#CD012300-bbs2-0010" title="HuangN , PalmerJ , SchidlowD , HsuanF , HsuC , GoldbergM , et al. Evaluation of antibiotic therapy in patients with cystic fibrosis. Chest1979;76(3):354‐5. [CENTRAL: 291362; CFGD Register: PI113a; CRS: 5500100000001409] HuangNN , PalmerJ , BravermanS , KeithHH , SchidlowD . Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study. 23rd Annual Meeting Cystic Fibrosis Club Abstracts; 1982 May 14; Washington D.C. 1982:124. [CENTRAL: 291363; CFGD Register: PI113b; CRS: 5500100000001410] ">Huang 1979</a>; <a href="./references#CD012300-bbs2-0014" title="LatzinP , FehlingM , BauernfeindA , ReinhardtD , KapplerM , GrieseM . Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. Journal of Cystic Fibrosis2008;7(2):142‐6. [CFGD Register: PI209] ">Latzin 2008</a>; <a href="./references#CD012300-bbs2-0016" title="MartinAJ , SmalleyCA , GeorgeRH , GealingDE , AndersonCM . Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis. Archives of Disease in Childhood1980;55:604‐7. [CENTRAL: 208487; CFGD Register: PI20; CRS: 5500100000001078] ">Martin 1980</a>; <a href="./references#CD012300-bbs2-0024" title="SchaadUB , Wedgwood KruckoJ , GueninK , BuehlmannU , KraemerR . Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. European Journal of Clinical Microbiology &amp; Infectious Diseases1989;8(10):858‐65. [CENTRAL: 64127; CFGD Register: PI63; CRS: 5500100000000416; PUBMED: 2512129] ">Schaad 1989</a>). Six trials studied eradication with no additional treatment once eradication had been achieved (<a href="./references#CD012300-bbs2-0011" title="KennyS , HallV , GoldsmithC , MooreJ , RendallJC , ElbornJS . Eradication of Pseudomonas aeruginosa in adults with CF. Journal of Cystic Fibrosis2009;8 Suppl 2:S39. [Abstract no.: 158; CFGD Register: PI229] ">Kenny 2009</a>; <a href="./references#CD012300-bbs2-0020" title="NCT01400750 . Comparison of 2 treatment regimens for eradication of p aeruginosa infection in children with cystic fibrosis [Prospective randomized trial comparing oral ciproxin plus inhaled colistin with tobramycin for inhalation for eradication of p aeruginosa infection in children with cystic fibrosis]. clinicaltrials.gov/show/NCT01400750 (first received 2011 July 22). [CENTRAL: CN‐01487718; CFGD Register: PI208e; CRS: 8243498] ProesmansM , BoulangerL , VermeulenF , DeBoeckK . Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ ciprofloxacin. Journal of Cystic Fibrosis2008;7 Suppl 2(Suppl 2):S64. [CFGD Register: PI208a] ProesmansM , BoulangerL , VermeulenF , DeBoeckK . Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin/ciprofloxacin. Pediatric Pulmonology2009;44 Suppl 32(S32):321. [Abstract no.: 311; CFGD Register: PI208b] ProesmansM , BoulangerL , VermeulenF , DeBoeckK . Eradication of recent pseudomonas aeruginosa infection: TOBI versus Colistineb®/ ciprofloxacin. Journal of Cystic Fibrosis2011;10 Suppl 1:S26. [Abstract no.: 102; CFGD Register: PI208c] ProesmansM , VermeulenF , BoulangerL , VerhaegenJ , DeBoeckK . Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2013;12(1):29‐34. [CFGDRegister: PI208d] ">Proesmans 2013</a>; <a href="./references#CD012300-bbs2-0026" title="CarianiL , DefilippiG , CostantiniD , ClautL , ClariziaG , D'accicoM , et al. Semi‐automated rep‐pcr genotyping of pseudomonas aeruginosa in Italian CF patients in eradication therapy. Pediatric Pulmonology2010;45(Suppl 33):348. [CFGD Register: PI230c] DolceD , CarianiL , RavenniN , MergniG , BiffiA , ColomboC , et al. Anti‐ P. aeruginosa antibodies and microbiological outcome in patients treated with early eradication therapy. Pediatric Pulmonology2013;48(Suppl 36):288. [CFGD Register: PI230i] EUCTR2008‐006502‐42‐IT . Early antibiotic treatment in pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols ‐ #FFC17/2007. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2008‐006502‐42‐IT (first posted 07 April 2010). [CENTRAL: CN‐01871008; CFGD Register: PI230j; CRS: 10770780] TaccettiG , BianchiniE , ZavataroL , CampanaS , DefilippiG , RavenniN , et al. Pseudomonas aeruginosa eradication in cystic fibrosis: preliminary data from a randomized multicenter study of two different early antibiotic treatment protocols. Pediatric Pulmonology2010;45 Suppl 33(S33):337. [Abstract no.: 332; CFGD Register: PI230d] TaccettiG , BianchiniE , ZavataroL , CampanaS , DefilippiG , RavenniN , et al. Pseudomonas aeruginosa microbiological status and emergence of other pathogens after early eradication treatment in cystic fibrosis: a post‐trial follow‐up. Pediatric Pulmonology2011;46 Suppl 34:317. [Abstract no.: 292; CFGD Register: PI230e] TaccettiG , BianchiniE , ZavataroL , CampanaS , RavenniN , BoniV , et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomized multicenter study of two different protocols. Pediatric Pulmonology2009;44 Suppl 32(S32):354. [Abstract no.: 406; CFGD Register: PI230a] TaccettiG , BianchiniE , ZavataroL , CostantiniD , GaliciV , CampanaS , et al. Pseudomonas aeruginosa eradication in cystic fibrosis: final results of a randomized multicenter study of two different early antibiotic treatment protocols. Pediatric Pulmonology2011;46(Suppl 34):317. [CFGD Register: PI230f] TaccettiG , CampanaS , FestiniF , MascheriniM , DoringG . Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. European Respiratory Journal2005;26(3):458‐61. [CENTRAL: CN‐01954292; CFGD Register: PI230k; CRS: 3510457; PUBMED: 16135728] TaccettiG , CocchiP , DolceD , GaliciV , MergniG , GagliardiniR , et al. Is early eradication treatment against P.aeruginosa associated with the emergence of other non‐fermenter gram negatives. Pediatric Pulmonology2013;48 Suppl 36:328. [Abstract no.: 338; CFGD Register: PI230h] TaccettiG , DolceD , CampanaS , RavenniN , FrancalanciM , MergniG , et al. Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing classic treatment protocols with classic treatment together with antibiotic treatment of upper airways. Multidisciplinary Respiratory Medicine2019;14 Suppl 1:5. [CENTRAL: CN‐01942483; CFGD Register: PI230l; CRS: 11485241; EMBASE: 627350044] Taccetti G , BianchiniE , CarianiL , BuzzettiR , CostantiniD , TrevisanF , et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax2012;67(10):853‐9. [CFGD Register: PI230g] ZavataroL , TaccettiG , CarianiL , RavenniN , BracciniG , BresciS , et al. Epidemiology of first/new Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis2010;9(Suppl 1):S29. [CFGD Register: PI230b] ">Taccetti 2012</a>; <a href="./references#CD012300-bbs2-0027" title="CazaresA , FigueroaW , KennaD , Langton‐HewerS , SmythA , WinstanleyC . Comparative genomics study of a set of Pseudomonas aeruginosa isolates from the TORPEDO‐CF trial. Journal of Cystic Fibrosis2019;18 Suppl 1:S1. [Abstract no.: WS01‐2; CENTRAL: CN‐01989497; CFGD Register: PI299h; CRS: 12180811; EMBASE: 2001976388] EUCTR2009‐012575‐10‐SE . Trial of optimal therapy for pseudomonas eradication in cystic fibrosis ‐ TORPEDO‐CF. www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2009‐012575‐10‐SE2016. [CENTRAL: CN‐01798235; CFGD Register: PI299d; CRS: 10698253] ISRCTN02734162 . Trial of optimal therapy for pseudomonas eradication in cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN02734162 (first received 22 May 2009). [CENTRAL: CN‐01807478; CFGD Register: PI299f; CRS: 10707427] Langton HewerS . TORPEDO‐CF. www.controlled‐trials.com/ISRCTN02734162/torpedo‐cf (first received 10 October 2011). [CFGD Register: PI299c] Langton HewerS , HickeyH , JonesA , BlundellM , SmythAR , on behalf of the TORPEDO‐CF contributors. TORPEDO‐CF‐completion of recruitment to trial of optimal regimen for eradication of new infection with Pseudomonas aeruginosa. Journal of Cystic Fibrosis2017;16 Suppl 1:S80. [CFGD Register: PI299a] Langton HewerS , SmythAR , JonesA , WilliamsonP . Torpedo‐CF – trial of optimal therapy for pseudomonas eradication in cystic fibrosis. Pediatric Pulmonology2018;53(S2):294. [CFGD Register: PI299b] Langton HewerSC , SmythAR , JonesAP , BrownM , HickeyH , WilliamsonPR , et al. Effectiveness of IV compared to oral eradication therapy of Pseudomonas aeruginosa in cystic fibrosis: multicentre randomised controlled trial (TORPEDO‐CF). Journal of Cystic Fibrosis2019;18 Suppl 1:S1. [Abstract no.: WS01‐1; CENTRAL: CN‐01986089; CFGD Register: PI299g; CRS: 12177837; EMBASE: 2001976729] SmythAR , Langton HewerS , BrownM , JonesA , HickeyH , KennaD , et al. Intravenous vs oral antibiotics for eradication of pseudomonas aeruginosa in cystic fibrosis (Torpedo‐CF): a randomised controlled trial. Pediatric Pulmonology2019;54(S2):302. [Abstract no.: 390; CENTRAL: CN‐01986111; CFGD Register: PI299i; CRS: 12177856; EMBASE: 629388639] University of Liverpool Clinical Trials Research Centre. TORPEDO‐CF. www.controlled‐trials.com/ISRCTN02734162/torpedo‐cf (first received 10 October 2011). [CENTRAL: CN‐01933136; CFGD Register: PI299e; CRS: 3510459] ">TORPEDO Trial</a>; <a href="./references#CD012300-bbs2-0028" title="ValeriusNH , KochC , HoibyN . Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet1991;338(8769):725‐6. [CENTRAL: 78099; CFGD Register: PI70b; CRS: 5500100000000484; PUBMED: 1679870] ValeriusNH , KochC , HoibyN . Prevention of chronic colonization with Pseudomonas aeruginosa in patients with CF by early treatment with ciprofloxacin and colistin aerosol inhalations. Pediatric Pulmonology1990;9 Suppl 5:248. [Abstract no.: 219; CENTRAL: 291624; CFGD Register: PI70a; CRS: 5500100000001626] ">Valerius 1991</a>; <a href="./references#CD012300-bbs2-0029" title="RatjenF , SteinkampG , DoringG , BauernfeindA , WiesemannHG , Von DerHardtH . Prevention of chronic pseudomonas aeruginosa infection by early inhalation therapy with tobramycin. Pediatric Pulmonology1994;Suppl 10:255. [CENTRAL: 291534; CFGD Register: PI101a; CRS: 5500100000001553] WiesemannHG , SteinkampG , RatjenF , BauernfeindA , PrzyklenkB , DoringG , et al. Placebo‐controlled, double‐blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatric Pulmonology1998;25(2):88‐92. [CENTRAL: 682749; CFGD Register: PI101b; CRS: 5500100000003296; EMBASE: 1998078952; PUBMED: 9516091] ">Wiesemann 1998</a>); and four trials had no eradication step (<a href="./references#CD012300-bbs2-0002" title="BrettMM , SimmondsEJ , GhoneimAT , LittlewoodJM . The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Comment in: Arch Dis Child 1993 Mar;68(3):432. Archives of Disease in Childhood1992;67(9):1086‐8. [CENTRAL: 291223; CFGD Register: PI73; CRS: 5500100000001295] ">Brett 1992</a>; <a href="./references#CD012300-bbs2-0012" title="KnightRK , BattenJC , MearnsM . A double blind trial of cephalexin in cystic fibrosis patients with pseudomonas in the sputum. 9th Meeting European Working Group for Cystic Fibrosis; 1979 Jun 12‐13; Noordwijkerhout, the Netherlands. 1979:52. [CENTRAL: 291389; CFGD Register: PI124; CRS: 5500100000001431] ">Knight 1979</a>; <a href="./references#CD012300-bbs2-0015" title="Loening BauckeVA , MischlerE , MyersMG . A placebo‐controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis. Journal of Pediatrics1979;95(4):630‐7. [CENTRAL: 21139; CFGD Register: PI19b; CRS: 5500100000000098; PUBMED: 383934] Loening‐BauckeVA , MischlerEH , MyersMG . Cephalexin in cystic fibrosis: a placebo‐controlled study. Pediatric Research1978;12(4 Pt 2):495. [CENTRAL: 189031; CFGD Register: PI19c; CRS: 5500100000000980; EMBASE: 1978335753] Loening‐BaukeV , MischlerEH , MyersMG . Cephalexin compared to placebo in the management of patients with cystic fibrosis. 19th Cystic Fibrosis Club Abstracts; 1978. 1978:69. [CENTRAL: 291430; CFGD Register: PI19a; CRS: 5500100000001461] ">Loening 1979</a>; <a href="./references#CD012300-bbs2-0025" title="SinghSB , SheltonAU , KotekK , StarnerTD . A clinically‐embedded trial to evaluate the efficacy of interventions for pre‐pseudomonal pathogens. Pediatric Pulmonology2013;48 Suppl 36:335. [Abstract no.: 358; CENTRAL: 999884; CFGD Register: PI274; CRS: 5500127000000006] ">Singh 2013</a>). One trial compared three weeks versus three months of eradication treatment but did not look for eradication after the first three weeks (<a href="./references#CD012300-bbs2-0008" title="FrederiksenB , HansenA , KochC , HoibyN . Delay of recurrence of Pseudomonas aeruginosa in patients with cystic fibrosis with inhaled colistin and oral ciproxin: a comparison between 3 weeks and 3 months of treatment. Pediatric Pulmonology1997; Vol. 23 Suppl 14:288. [Abstract no: 298] FrederiksenB , PresslerT , KochC , HoibyN . Endpoints for evaluating early anti‐pseudomonal treatment: changes in pseudomonas prevalence and in pulmonary function. Pediatric Pulmonology2003; Vol. 25 Suppl 25:334. ">Frederiksen 1997</a>). One trial was cross‐over in design comparing TIS and placebo where participants first treated with TIS could go on to open‐label treatment, but this was optional (<a href="./references#CD012300-bbs2-0023" title="RatjenF , AlonN , MaykutR , LiuC , AngyalosiG . TOBI® for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study. Journal of Cystic Fibrosis2016;15 Suppl 1:S1. [Abstract no.: WS01.2; CFGD Register: PI290] RatjenF , MoellerA , McKinneyML , AsherovaI , AlonN , MaykutR , et al. Eradication of early P. aeruginosa infection in children &lt;7years of age with cystic fibrosis: the early study. Journal of Cystic Fibrosis2019; Vol. 18, issue 1:78‐85. [CFGD Register: PI290b; DOI: 10.1016/j.jcf.2018.04.002] ">Ratjen 2018</a>). </p> <p>One further trial required very careful consideration (<a href="./references#CD012300-bbs2-0022" title="ISRCTN80955954 . Elite study: the microbiological efficacy and safety of two treatment regimens of inhaled tobramycine nebuliser solution (TNS) for the treatment of early onset pseudomonas aeruginosa lower respiratory tract infection in subjects with cystic fibrosis. www.who.int/trialsearch/Trial2.aspx?TrialID=ISRCTN80955954 (first posted 12 September 2005). [CENTRAL: CN‐01835047; CFGD Register: PI197g; CRS: 10734939] NTR377 . ELITE study [The microbiological efficacy and safety of two treatment regimens of inhaled tobramycine nebuliser solution (TNS) for the treatment of early onset pseudomonas aeruginosa lower respiratory tract infection in subjects with cystic fibrosis. ‐ ELITE]. www.who.int/trialsearch/Trial2.aspx?TrialID=NTR377 (first posted 12 September 2005). [CENTRAL: CN‐01826219; CFGD Register: PI197f; CRS: 10726130] RatjenF , MunckA , CampelloV . Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the Elite study. Pediatric Pulmonology2006;41 Suppl 29:318. [CFGD Register: PI197b] RatjenF , MunckA , CampelloV . Safety of inhaled tobramycin nebuliser solution for treatment of early pseudomonas aeruginosa infection: first results from the ELITE study. Journal of Cystic Fibrosis2006;5 Suppl:S22. [CFGD Register: PI197a] RatjenF , MunckA , KhoP . Short and long‐term efficacy of inhaled tobramycin in early P. Aeruginosa infection: the ELITE study. Pediatric Pulmonology2008;43 Suppl 31:319. [CFGD Register: PI197d] RatjenF , MunckA , KhoP , AngyalosiG , ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax2010;65(4):286‐91. [CFGD Register: PI197e] RatjenF , StengleinS , MunckA . Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection; the ELITE study. Journal of Cystic Fibrosis2008;7 Suppl 2:S26. [CFGD Register: PI197c] ">Ratjen 2010</a>). This was a trial of eradication, rather than one of secondary prevention, in which all participants underwent 28 days of eradication for PA with TIS 300 mg twice daily. After this they were randomised to either no further therapy or to a further 28 days of TIS. Randomisation was based on the results of PA serology taken at baseline. Following discussion with the lead author, it was clear that respiratory cultures were not taken at day 28 to assess eradication, as participants were still on treatment, which may have suppressed PA growth. Since there was no measure of eradication between the initial 28‐day period and the subsequent period of either no treatment or an additional 28 days TIS this trial did not meet our inclusion criteria (see <a href="#CD012300-sec-0035">Types of participants</a>). </p> <section id="CD012300-sec-0065"> <h5 class="title">Ongoing studies</h5> <p>One ongoing trial seems to meet our inclusion criteria. A phase III trial examining the ability of IgY to prolong time to chronic PA infection following successful eradication is due to be published in 2019 (<a href="./references#CD012300-bbs2-0031" title="EUCTR2011‐000801‐39‐SE . Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosis [www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐000801‐39‐SE]. (first received 13 December 2011). [CFGD Register: PI252c] KollbergH , LarssonA , NilssonE . Anti‐pseudomonas IGY ready for phase III. Pediatric Pulmonology2010;45 Suppl 33:343. [Abstract no.: 345; CENTRAL: 848799; CFGD Register: PI252a; CRS: 5500100000003664] LarssonA . Phase III study (IMPACTT) on anti‐pseudomonas IgY. Journal of Cystic Fibrosis2011;10 Suppl 1:S24. [Abstract no.: 92; CENTRAL: 848800; CFGD Register: PI252b; CRS: 5500100000003666] NCT01455675 . Efficacy study of igy (antibody against pseudomonas) in cystic fibrosis patients [Phase III study to evaluate clinical efficacy and safety of avian polyclonal anti‐pseudomonas antibodies (igy) in prevention of recurrence of pseudomonas aeruginosa infection in cystic fibrosis patients]. clinicaltrials.gov/show/nct01455675 (first received 2011 October 20). [CENTRAL: CN‐01533433; CFGD Register: PE252e; CRS: 8286130] SchusterA , BendJ , HoibyN , VerdePE , RottmannA , LarssonA , et al. Clinical study to evaluate an anti‐Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011‐000801‐39). Journal of Cystic Fibrosis2019;18:S23. [Abstract no.: WS12‐5; CENTRAL: CN‐01990653; CFGD Register: PI252d; CRS: 12181829; EMBASE: 2001976053] ">Larsson 2011</a>). This is a double‐blind RCT comparing avian‐derived IgY antibodies in a 70 mL gargle to a volume‐matched placebo in participants with previously eradicated PA. Males and females aged five years or over, who were able to gargle and were PA negative at enrolment were eligible. A total of 164 participants were recruited from multiple European CF centres. The primary outcome for this trial was the time from enrolment to the first PA positive sputum, throat cough swab or endolaryngeal suction culture. Secondary outcomes included the change from baseline in FEV<sub>1</sub> and BMI, number of days of illness, number of days taking antibiotics, number of pulmonary exacerbations, the change in PA serum precipitins from baseline, safety and emergence of novel pathogens. </p> </section> <section id="CD012300-sec-0066"> <h5 class="title">Studies awaiting classification</h5> <p>The OPTIMIZE trial is a multicentre (45 sites in the USA) parallel RCT examining the effect of azithromycin in preventing pulmonary exacerbations in participants who have undergone PA eradication (<a href="./references#CD012300-bbs2-0030" title="Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early Pseudomonas infection in cystic fibrosis: the Optimize randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177‐87. [CFGD Register: MA31b; DOI: 10.1164/rccm.201802‐0215OC; PUBMED: 29890086] Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial [Erratum: Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial (American Journal of Respiratory and Critical Care Medicine (2018) 198 (1177–1187) DOI: 10.1164/rccm.201802‐0215OC)]. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CENTRAL: CN‐01967101; CFGD REgister: MA31d; CRS: 11932900; DOI: 10.1164/rccm.201802‐0215OC; EMBASE: 2001700512; PUBMED: 30874457] NCT02054156 . Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis [Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis: the OPTIMIZE multicenter, placebo‐controlled, double‐blind, randomized trial]. clinicaltrials.gov/show/NCT02054156 (first received 2014 February 04). [CENTRAL: CN‐01543461; CFGD Register: MA31c; CRS: 8295539] RamseyBW , Retsch‐BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52 Suppl 47:380‐1. [Abstract no. : 434; CFGD Register: MA31a] ">OPTIMIZE 2018</a>). Participants were randomised in a 1:1 ratio, but stratified by age group. The trial was blinded four ways (participant, care provider, investigator, outcomes assessor). The trial planned for an 18‐month follow‐up but was terminated early when it reached a pre‐specified interim monitoring boundary for efficacy. The median length of follow‐up for this trial was therefore 11.8 months. Investigators enrolled 221 participants aged six months to 18 years in this trial. Participants had to have either lifetime first isolation of PA or a new isolation, defined as at least a two‐year absence of PA having had at least one respiratory culture examined per year. The positive PA sample had to be within 40 days of the baseline visit; TIS therapy could have started up to 14 days prior to this visit. All participants underwent an initial course of inhaled TIS 300 mg twice daily for 28 days. This could be extended for a further 28 days if samples taken at the week 3 visit remained positive for PA. The active intervention was oral azithromycin suspension at 10 mg/kg up to a maximum dose of 500 mg, three times a week for the duration of the trial; participants in the control group received a volume‐matched placebo. The primary end‐point was time to next pulmonary exacerbation. This was defined a priori as a pulmonary exacerbation treated with any mode of antibiotics (oral, inhaled or intravenous). Secondary endpoints included safety (monitored by adverse events and audiology), changes in height, weight and lung function, time to recurrence of PA after the first quarter of treatment, electrocardiogram (ECG) changes, frequency of exacerbations, frequency of PA positive cultures, rates of antibiotic usage, rates of hospitalisations and patient/parent reported changes in the Chronic Respiratory Infection Symptom Score (CRISS). </p> <p>Initial results of this trial have been published; however, it is likely only a subsection of participants will be eligible for our review and IPD will not be available for analysis until the trial is published in full (<a href="./references#CD012300-bbs2-0030" title="Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early Pseudomonas infection in cystic fibrosis: the Optimize randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177‐87. [CFGD Register: MA31b; DOI: 10.1164/rccm.201802‐0215OC; PUBMED: 29890086] Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial [Erratum: Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial (American Journal of Respiratory and Critical Care Medicine (2018) 198 (1177–1187) DOI: 10.1164/rccm.201802‐0215OC)]. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CENTRAL: CN‐01967101; CFGD REgister: MA31d; CRS: 11932900; DOI: 10.1164/rccm.201802‐0215OC; EMBASE: 2001700512; PUBMED: 30874457] NCT02054156 . Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis [Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis: the OPTIMIZE multicenter, placebo‐controlled, double‐blind, randomized trial]. clinicaltrials.gov/show/NCT02054156 (first received 2014 February 04). [CENTRAL: CN‐01543461; CFGD Register: MA31c; CRS: 8295539] RamseyBW , Retsch‐BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52 Suppl 47:380‐1. [Abstract no. : 434; CFGD Register: MA31a] ">OPTIMIZE 2018</a>). </p> </section> </section> </section> <section id="CD012300-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged the trial to have an unclear overall risk of bias (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). There is a low risk of bias for all domains except 'other potential sources of bias' which is unclear due to the potential for additional anti‐PA therapy to be given prior to commencing the trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). We have summarised risk of bias in <a href="#CD012300-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012300-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012300-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012300-sec-0068"> <h4 class="title">Allocation</h4> <section id="CD012300-sec-0069"> <h5 class="title">Sequence generation</h5> <p>We deemed the risk of bias from sequence generation to be low (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). The trial described the processes of randomisation clearly, both in the main paper and in supplementary information. Investigators generated a randomisation code using a computerised random number generator. </p> </section> <section id="CD012300-sec-0070"> <h5 class="title">Allocation concealment</h5> <p>We deemed the risk of bias due to allocation concealment to be low since an interactive voice‐response system confirmed treatment allocation via email (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0071"> <h4 class="title">Blinding</h4> <section id="CD012300-sec-0072"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>The trial blinded all participants and personnel to oral therapy (ciprofloxacin or placebo). Bayer Pharmaceuticals Inc. provided both active and placebo tablets and suspension; the placebo suspension was taste‐masked. However, in this trial the allocation to cycled therapy or culture‐based therapy was open‐label for participants and care providers (although the core trial investigators were blinded to all treatment allocation for the whole trial). In an attempt to reduce the risk of bias from the lack of blinding the trial used an a priori definition of a pulmonary exacerbation and investigators reviewed all hospitalisation records in conjunction with symptom diaries from the participants to ensure that this definition was met. In view of these additional measures we deemed the risk of bias for this domain to be low (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0073"> <h5 class="title">Blinding of outcome assessors (detection bias)</h5> <p>We deemed the risk of detection bias to be low as it was explicitly stated that, "The core study investigators were blinded to all treatment allocation for the entire study" (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>The trial report stated the investigators used an intention‐to‐treat analysis for their primary outcome measures (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). In reality this was a modified intention‐to‐treat analysis (all randomised participants who received at least one dose of the trial drug) as two randomised participants failed screening prior to starting any trial medications and were therefore excluded from the analysis; they did not describe how data were imputed (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Investigators described withdrawals; these were small numbers and were balanced across the groups for both numbers and explanation (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). We therefore judged this domain to have a low risk of bias. </p> </section> <section id="CD012300-sec-0075"> <h4 class="title">Selective reporting</h4> <p>We were able to examine the published protocol on the trials registry <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). In addition, we analysed the published methodology. We assessed this domain as having a low risk of bias, investigators reported all the stated outcome measures in the paper, the online supplement and provided additional data in the online trial entry (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>The trial was supported by industry in the provision of medications (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). The paper specifically states that, "The industry sponsors had no role in the analysis, interpretation and writing of the manuscript". </p> <p>The trial defined new onset PA as either a first lifetime PA isolation or isolation after two years PA‐free with at least one culture per year (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). This frequency of respiratory tract sampling is low; USA Infection Control Guidelines recommend sampling be done quarterly (<a href="./references#CD012300-bbs2-0091" title="SaimanL , SiegelJD , LiPumaJJ , BrownRF , BrysonEA , ChambersMJ , et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infection Control &amp; Hospital Epidemiology2014;35 Suppl 1:S1‐S67. ">Saiman 2014</a>) and UK guidelines recommend sampling every two months (<a href="./references#CD012300-bbs2-0042" title="UK Cystic FibrosisTrust . Antibiotic Treatment for Cystic Fibrosis – 3rd edition. Report of the UK Cystic Fibrosis Trust Antibiotic Group. www.cysticfibrosis.org.uk/media/82010/antibiotic‐treatment‐for‐cystic‐fibrosis‐may‐09.pdf (accessed 08 December 2015). ">Cystic Fibrosis Trust 2009</a>). It has been shown that a single sputum culture will identify only 58% of the bacterial diversity identified though more invasive sampling (<a href="./references#CD012300-bbs2-0088" title="RogersGB , SkeltonS , SerisierDJ , van derGastCJ , BruceKD . Determining cystic fibrosis‐affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. Journal of Clinical Microbiology2010;48(1):78‐86. ">Rogers 2010</a>); PA may therefore have been unknowingly present for longer than the time limits set between positive culture and enrolment, affecting the chance of successful eradication. In addition participants were allowed to have had a positive PA culture within six months of eradication and to have had up to one course of anti‐PA therapy prior to enrolment. This additional therapy may have affected the chance of eradication and the subsequent success of the trial regimens (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <p>The trial did not specifically answer the question posed in this review (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). We made a practical decision to define eradication as PA negative culture at visit 2 and analysed the subset of participants who fulfilled this definition. This may have had an impact on selection bias as not all participants allocated to each group were analysed for our review and the trial was not powered for this end‐point. </p> <p>Overall we judged the trial to have an unclear risk of other potential bias (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0077"> <h3 class="title" id="CD012300-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD012300-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: cycled versus culture‐based antibiotic therapy for preventing recurrence of infection with <i>Pseudomonas aeruginosa</i> </a> </p> <section id="CD012300-sec-0078"> <h4 class="title">Cycled versus culture‐based therapy</h4> <p>Data are reported below from the eligible subset of the trial population from the only included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). For the whole trial cohort, 304 participants were included in the intention‐to‐treat population and data for 300 were made available for analysis (consent for data sharing was not provided by the other four). </p> <p>We defined successful eradication as individuals who were PA negative at visit 2 (median 21 days). Whilst trial participants who were PA positive at this visit were allowed within the trial design to have a second course of tobramycin (up to 56 days) to maximise the chance of eradication, this would have added bias to our review since not all participants would have had the same eradication regimen. We conducted a sensitivity analysis for the primary outcome to assess the impact of this decision. </p> <p>At the second trial visit 41 participants were PA positive and were excluded from the analysis. A further six participants had no result or an inconclusive result at this time point and were also excluded from the analysis. Thus the eligible subset included 253 participants, 119 in the cycled arm and 134 in the culture‐based arm. Of these, 64 out of 119 (53.8%) participants in the cycled group were in the ciprofloxacin arm of the ciprofloxacin versus placebo trial and 70 out of 134 (52.2%) participants in the culture‐based group were also in the ciprofloxacin arm. </p> <section id="CD012300-sec-0079"> <h5 class="title">Primary outcomes</h5> <section id="CD012300-sec-0080"> <h6 class="title">1. Time to next isolation of PA</h6> <p>The time to next isolation of PA was not reported in the published trial report, but could be calculated from the IPD provided. The median follow‐up for the included participants was 494 days and in the cycled group 26 out of 119 participants had recurrent PA during follow‐up while in the culture‐based group 54 out of 134 participants experienced a recurrence of PA. We were unable to measure the median time to recurrence as fewer than 50% of participants in each group had experienced a recurrence at the end of the trial. The time to recurrent PA favoured cycled over culture‐based therapy. The HR, calculated using the Cox Proportional Hazards Model, for recurrence of PA in the culture‐based group compared to the cycled group was 2.04 (95% CI 1.28 to 3.26) (<a href="./references#CD012300-fig-0003" title="">Analysis 1.1</a>). The proportional hazards assumption was checked and found to hold (P = 0.68). The GRADE rating for this evidence was moderate; it was downgraded once for indirectness (only examined children aged one to 12 years old) (<a href="./full#CD012300-tbl-0001">summary of findings Table for the main comparison</a>). This is in contrast to the main trial report which examined rates of PA positivity (rather than time to recurrent PA) and found no difference between the cycled an culture‐based groups (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <p>To assess the effect of the decision to use PA negativity at visit 2 to define eradication we conducted a sensitivity analysis using PA negativity at visit 3. For this analysis 244 participants were eligible, 123 in the cycled arm and 121 in the culture‐based arm. In the cycled group 25 out of 123 (20.3%) participants had recurrent PA during follow‐up, while in the culture‐based arm 44 out of 121 (36.4%) participants experienced a recurrence. Again, the median time to recurrence could not be calculated. The HR, calculated as above using the Cox Proportional Hazards Model, for recurrence of PA in the culture‐based group compared to the cycled group was 1.98 (95% CI 1.21 to 3.23) (<a href="./references#CD012300-fig-0004" title="">Analysis 1.2</a>). 19 of 123 (15.5%) participants in the cycled group had additional TIS therapy compared to 7 out of 121 (5.8%) participants in the culture‐based group. The proportional hazards assumption was checked and found to hold (P = 0.96). </p> </section> </section> <section id="CD012300-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD012300-sec-0082"> <h6 class="title">1. Change in QoL from baseline</h6> <p>This was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0083"> <h6 class="title">2. Change from baseline for pulmonary function tests</h6> <p>The included trial looked at participants aged between one and 12 years old (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Pulmonary function testing was only performed in participants aged four years or over who were able to perform spirometry; hence at the end of trial follow‐up visit data were only available for 130 participants. </p> <section id="CD012300-sec-0084"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The Treggiari paper reports the absolute mean (SD) change from baseline of FEV<sub>1</sub> and FEV<sub>1</sub> % predicted at the end of trial visit (week 70) (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Using the IPD provided we were able to analyse the mean (SD) absolute and relative change from baseline for FEV<sub>1</sub> L and FEV<sub>1</sub> % predicted at 'up to three months', 'up to six months', 'up to one year', and 'up to two years'. The GRADE of this evidence was very low. It was downgraded three times for indirectness (the results only relate to children), incomplete outcome data (only 131 out of 252 participants) and small sample size (<a href="./full#CD012300-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>There were no differences identified between the cycled or culture‐based therapies for any of the measurements of FEV<sub>1</sub> reported at any time point: absolute change from baseline in L (<a href="./references#CD012300-fig-0005" title="">Analysis 1.3</a>), relative change from baseline in L (<a href="./references#CD012300-fig-0006" title="">Analysis 1.4</a>), absolute change from baseline in % predicted (<a href="./references#CD012300-fig-0007" title="">Analysis 1.5</a>), or relative change from baseline in % predicted (<a href="./references#CD012300-fig-0008" title="">Analysis 1.6</a>) (all very low‐quality evidence). </p> </section> <section id="CD012300-sec-0085"> <p><b>b. FVC</b></p> <p>The published Treggiari paper does not report changes in FVC, in either L or % predicted (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Using the IPD provided we were able to analyse the mean (SD) absolute and relative change from baseline for FVC (L) at 'up to three months', 'up to six months', 'up to one year', and 'up to two years'. </p> <p>There was no difference in absolute change of FVC (L) from baseline (<a href="./references#CD012300-fig-0009" title="">Analysis 1.7</a>) or relative change of FVC from baseline between the cycled and culture‐based groups at any of the time points analysed (<a href="./references#CD012300-fig-0010" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD012300-sec-0086"> <h6 class="title">3. Pulmonary exacerbations</h6> <section id="CD012300-sec-0087"> <p><b>a. time to next exacerbation</b></p> <p>The primary outcome of the included trial was the time to next pulmonary exacerbation (in days) meeting their a priori definition and requiring either intravenous antibiotic or hospitalisation; the investigators reported no difference between cycled therapy and culture‐based for the entire cohort, HR 0.95 (95% CI 0.54 to 1.66) (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011)</a>. </p> <p>We used the trial's secondary outcome, pulmonary exacerbation (using the trial definition) requiring any antibiotic therapy (intravenous, inhaled or oral) for our definition of a pulmonary exacerbation (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). For our subset of participants data were available for 253 participants, 119 in the cycled group and 134 in the culture‐based group. Four participants experienced a pulmonary exacerbation prior to commencement of trial medication and were excluded from analysis. Data were therefore available from 249 participants. We found no difference in the time to next pulmonary exacerbation (in days) between participants in the cycled arm and those in the culture‐based arm (<a href="./references#CD012300-fig-0011" title="">Analysis 1.9</a>). The median time to next pulmonary exacerbation was 518 days in the cycled group and 495 days in the culture‐based group. The interquartile range was not calculable for either group as 75% of participants had not undergone a pulmonary exacerbation by the end of the trial. </p> </section> <section id="CD012300-sec-0088"> <p><b>b. frequency of exacerbations</b></p> <p>The trial reported the number of participants who experienced a pulmonary exacerbation and for our participant subset data were available for 253 participants (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). There was no difference in the number of participants experiencing a pulmonary exacerbation between groups (<a href="./references#CD012300-fig-0012" title="">Analysis 1.10</a>). The GRADE rating of this evidence was moderate. It was downgraded once for indirectness as the results only relate to children (<a href="./full#CD012300-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>There was no difference in the frequency of exacerbations per participant between the groups (<a href="./references#CD012300-fig-0013" title="">Analysis 1.11</a>). </p> <p>The mean (SD) frequency of additional courses of antibiotics was 2.50 (2.21) in the cycled group and 3.34 (2.78) in the culture‐based group; analysis of these data clearly favoured the cycled group, MD ‐0.85 (95% CI ‐1.46 to ‐0.23) (<a href="./references#CD012300-fig-0013" title="">Analysis 1.11</a>). </p> </section> <section id="CD012300-sec-0089"> <p><b>c. number of days in hospital</b></p> <p>The trial reported number of hospitalisations, but not the number of days in hospital (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0090"> <h6 class="title">4. Nutritional parameters</h6> <section id="CD012300-sec-0091"> <p><b>a. weight (kg) and weight centile or Z score</b></p> <p>The Treggiari paper reports the absolute mean (SD) change in weight (kg) from baseline at the end of trial visit (week 70) (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>) but does not report changes in weight percentile. Using the IPD provided we were able to analyse the mean (SD) absolute change from baseline for weight and weight percentile at 'up to three months', 'up to six months', 'up to one year', and 'up to two years'. </p> <p>There was no difference at any of the time points analysed between the cycled and culture‐based groups in either absolute change in weight (kg) or change in weight percentile (<a href="./references#CD012300-fig-0014" title="">Analysis 1.12</a>; <a href="./references#CD012300-fig-0015" title="">Analysis 1.13</a>) . </p> </section> <section id="CD012300-sec-0092"> <p><b>b. height (cm) (children) and height centile or Z score</b></p> <p>The Treggiari paper reports the absolute mean (SD) change in height (cm) from baseline at the end of trial visit (week 70) (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>) but does not report changes in height percentile. Using the IPD provided we were able to analyse the mean (SD) absolute change from baseline for height and change in height percentile from baseline at 'up to three months', 'up to six months', 'up to one year', and 'up to two years'. </p> <p>There was no difference in absolute change in height (cm) or change in height percentile between the cycled and culture‐based groups at any of the time points analysed (<a href="./references#CD012300-fig-0016" title="">Analysis 1.14</a>; <a href="./references#CD012300-fig-0017" title="">Analysis 1.15</a>) . </p> </section> <section id="CD012300-sec-0093"> <p><b>c. BMI and BMI centile</b></p> <p>This outcome was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0094"> <h6 class="title">5. Time to chronic PA infection</h6> <p>This outcome was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0095"> <h6 class="title">6. Adherence to treatment</h6> <section id="CD012300-sec-0096"> <p><b>a. self‐reported measures</b></p> <p>This outcome was not reported in the included trial and data were not available to calculate the results (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0097"> <p><b>b. secondary count measures</b></p> <p>In the Treggiari trial adherence was measured by counting returned medication (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). In the published paper there is a comment that, "compliance with study mediations [was] 90% or greater across treatment groups," but no data are presented. Using the IPD provided we were able to analyse the number of participants returning any trial medication and the number of participants returning tobramycin at 'up to three months', 'up to six months', 'up to one year', and 'up to two years'. </p> <p>There was no difference between the cycled and culture‐based groups in the percentage of participants returning any trial medication at any of the time‐points analysed (<a href="./references#CD012300-fig-0018" title="">Analysis 1.16</a>) or in the proportion of participants returning tobramycin at any of the time‐points analysed (<a href="./references#CD012300-fig-0019" title="">Analysis 1.17</a>). </p> <p>Adherence to tobramycin (inhaled) was better than adherence to overall trial medication at all time points (<a href="./references#CD012300-fig-0018" title="">Analysis 1.16</a>; <a href="./references#CD012300-fig-0019" title="">Analysis 1.17</a>). However, the forest plot examining the number of participants who returned no trial medication appears to show a trend towards better adherence in the culture‐based group over time (<a href="./references#CD012300-fig-0018" title="">Analysis 1.16</a>). </p> </section> <section id="CD012300-sec-0098"> <p><b>c. electronic data</b></p> <p>This was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0099"> <h6 class="title">7. Adverse effects of treatment</h6> <p>The published trial report only reported rates of serious adverse events; they reported no difference in the rate of these between intervention groups (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <section id="CD012300-sec-0100"> <p><b>a. mild</b></p> <p>Mild adverse events were not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0101"> <p><b>b. moderate</b></p> <p>Moderate adverse events were not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0102"> <p><b>c. severe</b></p> <p>A total of 49 out of 253 (19.4%) participants in our subset experienced a severe adverse event during the course of the trial; this was not significantly different between the cycled and culture‐based groups (<a href="./references#CD012300-fig-0020" title="">Analysis 1.18</a>). There was no significant difference in the rate of severe adverse events in any of the categories studied (respiratory, infection, gastro‐intestinal, metabolism, musculoskeletal, nervous system, skin or other) (<a href="./references#CD012300-fig-0020" title="">Analysis 1.18</a>). The GRADE rating for this evidence was moderate; it was downgraded once for applicability since the participants were all children (<a href="./full#CD012300-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD012300-sec-0103"> <h6 class="title">8. Mortality</h6> <p>This outcome was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0104"> <h6 class="title">9. Isolation of resistant bacteria</h6> <section id="CD012300-sec-0105"> <p><b>a. PA with a new resistance pattern or novel mucoid PA</b></p> <p>The trial reported on the emergence of PA newly resistant to ciprofloxacin or tobramycin and novel identification of mucoid PA (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). The included subset of participants were sampled at six time points after the visit 2 sample which defined inclusion in the trial. The 119 participants in the cycled arm provided a median (range) of six (zero to six) samples; in the culture‐based arm 134 participants provided a median (range) of six (zero to six) samples. </p> <p>There was no significant difference in the rate of detection of PA newly resistant to either ciprofloxacin or tobramycin between the cycled and culture‐based groups (<a href="./references#CD012300-fig-0021" title="">Analysis 1.19</a>). </p> <p>Isolation of novel mucoid PA was not significantly different between the groups (<a href="./references#CD012300-fig-0022" title="">Analysis 1.20</a>). </p> </section> <section id="CD012300-sec-0106"> <p><b>b. MRSA</b></p> <p>The included trial reported the novel identification of <i>Staphylococcus aureus,</i> but this was not further specified as methicillin‐sensitive <i>Staphylococcus aureus</i> (M<i>S</i> SA) versus methicillin‐resistant <i>Staphylococcus aureus</i> (MRSA) (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> <section id="CD012300-sec-0107"> <p><b>c. resistant gram negative organisms</b></p> <p>The Treggiari trial reported on the emergence of novel <i>Stenotrophomonas maltophilia</i> , <i>Achromobacter xylosoxidans</i> and <i>Burkholderia cepacia</i> complex (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). The included subset of participants were sampled at six time points after the visit two sample which defined inclusion in the trial. In the cycled arm, 119 participants provided a median (range) of six (zero to six) samples and in the culture‐based arm 134 participants provided a median (range) of six (zero to six) samples. There was no significant difference between groups (<a href="./references#CD012300-fig-0023" title="">Analysis 1.21</a>). The GRADE rating for this evidence was moderate. It was downgraded once for indirectness (<a href="./full#CD012300-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD012300-sec-0108"> <p><b>d. other novel organisms</b></p> <p>The trial did not report on the emergence of any other novel pathogens (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> <section id="CD012300-sec-0109"> <h6 class="title">10. Cost effectiveness</h6> <p>This outcome was not reported in the included trial (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012300-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012300-sec-0110"></div> <p>Only one trial with participants who fulfilled our inclusion criteria was identified and only a subset of the 306 participants enrolled in this trial were eligible (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). IPD was obtained for 300 participants, of whom 253 were eligible to be included in our review. </p> <section id="CD012300-sec-0111"> <h3 class="title" id="CD012300-sec-0111">Summary of main results</h3> <p>Our analysis showed that additional treatment with inhaled tobramycin every three months (cycled therapy) following eradication of PA doubled the time to recurrence of PA in a subset of participants from the EPIC trial compared to culture‐based therapy (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>) (<a href="./references#CD012300-fig-0003" title="">Analysis 1.1</a>). This was not affected by changing the definition of eradication (<a href="./references#CD012300-fig-0004" title="">Analysis 1.2</a>). We deemed the quality of the evidence for our primary outcome to be moderate suggesting there is probably an improvement in time to recurrence after cycled therapy. Development of newly‐resistant PA and isolation of newly‐resistant organisms were slightly higher in the culture‐based group compared to the cycled group, but this result was not statistically significant. There was no evidence of a difference between the treatment groups in terms of pulmonary function, time to next pulmonary exacerbation, severe adverse events, nutritional parameters, adherence, isolation of newly mucoid PA or novel resistant gram negative organisms. The quality of evidence for secondary outcomes was moderate according to GRADE criteria with the exception of pulmonary function which was deemed to be very low, meaning that we are uncertain whether there is an effect. The trial did not report on QoL, time to chronic PA infection, mortality or cost‐effectiveness (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). </p> <p>In the published trial report, the authors concluded that there was no difference between cycled and culture‐based therapy in the rate of pulmonary exacerbation or PA positivity (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). This is in contrast to the findings of our review, where we found that the time to next isolation of PA was doubled by the provision of cycled TIS therapy. The difference in these findings could be due to the fact that only a subset of the trial's enrolled participants were eligible for inclusion in our review; although the baseline characteristics of our subset were similar to those of the whole cohort described in the main trial report except that the percentage of participants positive for PA at baseline in the cycled group was only 27.4% in our subset, compared to 38% in the full cohort (<a href="./references#CD012300-sec-0130" title="">Characteristics of included studies</a>). Another explanation could be the different question posed by this review compared to the main trial, namely the time to next isolation of PA rather than the rate of PA positivity in each group (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). An additional consideration is that the results in the main trial report were age‐adjusted, which is not the case for the results presented here. </p> </section> <section id="CD012300-sec-0112"> <h3 class="title" id="CD012300-sec-0112">Overall completeness and applicability of evidence</h3> <p>The included trial only included children up to 12 years of age (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). Eradication can be successful in adults with CF (<a href="./references#CD012300-bbs2-0071" title="Langton HewerSC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD004197.pub5] ">Langton Hewer 2017</a>); the age at onset of chronic PA infection is increasing (<a href="./references#CD012300-bbs2-0044" title="Cystic FibrosisTrust . UK Cystic Fibrosis Registry Annual Data Report 2017. www.cysticfibrosis.org.uk/the‐work‐we‐do/uk‐cf‐registry/reporting‐and‐resources. London: Cystic Fibrosis Trust, (accessed prior to 27 July 2019). ">Cystic Fibrosis Trust 2018</a>) and the percentage of individuals with a PA positive culture is decreasing (<a href="./references#CD012300-bbs2-0041" title="Cystic Fibrosis Foundation [US]. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. www.cff.org/Research/Researcher‐Resources/Patient‐Registry/2017‐Patient‐Registry‐Annual‐Data‐Report.pdf. Bethesda, Maryland, (accessed prior to 29 July 2019). ">Cystic Fibrosis Foundation 2018</a>). Strategies to prevent the recurrence of PA after successful eradication are therefore important for all age groups, but the findings of this review cannot be directly applied to adolescents and adults with CF. The paucity of trials also meant that we were not able to comment on some of our outcomes (changes in QoL, time to chronic PA infection, mortality and cost‐effectiveness). </p> <p>The trial allowed inclusion of participants whose PA‐positive qualifying sample occurred up to six months prior to the baseline visit. Participants could have undergone up to one course of eradication therapy prior to enrolment. This may have had an effect on the efficacy of the intervention, either biasing it towards participants who had previously undergone eradication or conversely biasing it towards participants with only a short lag between PA identification and the commencement of treatment. Results from the EARLY trial suggest that a delay in the commencement of eradication therapy for PA negatively affects the chance of success (<a href="./references#CD012300-bbs2-0023" title="RatjenF , AlonN , MaykutR , LiuC , AngyalosiG . TOBI® for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study. Journal of Cystic Fibrosis2016;15 Suppl 1:S1. [Abstract no.: WS01.2; CFGD Register: PI290] RatjenF , MoellerA , McKinneyML , AsherovaI , AlonN , MaykutR , et al. Eradication of early P. aeruginosa infection in children &lt;7years of age with cystic fibrosis: the early study. Journal of Cystic Fibrosis2019; Vol. 18, issue 1:78‐85. [CFGD Register: PI290b; DOI: 10.1016/j.jcf.2018.04.002] ">Ratjen 2018</a>). </p> <p>The included trial followed up participants for a median of 494 days. Up to this point there was no evidence of difference between the two groups (cycled therapy or culture‐based therapy) in terms of clinical parameters (lung function, nutritional parameters, time to next pulmonary exacerbation), thus although PA recurrence was delayed in the cycled group, this was not translated into objective clinical benefit. Chronic PA infection is associated with increased morbidity and mortality, but it may be that longer follow‐up is required to truly appreciate whether cycled therapy has a clinically apparent benefit. </p> <p>It is also important to note that the included trial does not directly address the question posed in this review (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>). The same problem applies to all currently‐designed eradication studies. Treggiari aimed to compare prolonged eradication regimens to reduce the chance of pulmonary exacerbation after the acquisition of PA. Evidence of eradication was not a requirement in the trial protocol prior to the commencement of the trial. We therefore had to use a proxy measure of eradication and could only include a subset of participants from the trial, which reduces the applicability of the evidence to this review question. The use of a single negative culture result (which may have been an OPC culture) further reduces the applicability of the evidence for two reasons. Firstly, the visit 2 sample was taken while the participant was still on treatment so a negative result may represent suppression rather than true eradication; and secondly, since a single sputum sample may only identify 58% of the bacterial diversity compared to more intensive sampling, this may be insufficient to be certain that eradication has occurred (<a href="./references#CD012300-bbs2-0088" title="RogersGB , SkeltonS , SerisierDJ , van derGastCJ , BruceKD . Determining cystic fibrosis‐affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. Journal of Clinical Microbiology2010;48(1):78‐86. ">Rogers 2010</a>). </p> </section> <section id="CD012300-sec-0113"> <h3 class="title" id="CD012300-sec-0113">Quality of the evidence</h3> <p>We have identified only one trial to include in this review and examined data from 252 participants (<a href="./references#CD012300-bbs2-0001" title="AnsteadM , HeltsheSL , KhanU , BarbieriJT , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology and risk for re‐isolation in the EPIC trial. Journal of Cystic Fibrosis2013;12(2):147‐53. [CFGD Register: PI202m] AnsteadM , LympJ , KhanU , BarbieriJ , LangkampM , DoringG , et al. Pseudomonas aeruginosa serology predicts response to treatment and re‐infection in the EPIC clinical study. Pediatric Pulmonology2011;46 Suppl 34:303. [Abstract no.: 254; CFGD Register: PI202g] AnsteadM , SaimanL , Mayer‐HamblettN , LandsLC , KlosterM , GossCH , et al. Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis2014;13(1):74‐9. [CFGD Register: PI202l] HamblettNM , Retsch‐BogartGZ , TreggiariM , KronmalRA , KhanU , WilliamsJ , et al. Safety and efficacy of anti‐pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study. Pediatric Pulmonology2009;44 Suppl 32:183. [CFGD Register: PI202b] HamblettNM , RosenfeldM , KlosterM , GibsonR , Retsch‐BogartGZ , ThompsonV , et al. Impact of successful eradication of pseudomonas aeruginosa on long term outcomes in cystic fibrosis. Pediatric Pulmonology2014;49(S38):317. [Abstract no.: 283; CENTRAL: CN‐01057040; CFGD Register: PI202q; CRS: 1787622; EMBASE: 71616335] HoffmanLR , RamseyBW , KulasekaraHD , Retsch‐BogartGZ , WolterDJ , PopeCE , et al. Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial. Pediatric Pulmonolgy2012;47 Suppl 35:317. [Abstract no.: 266; CFGD Register: PI202j] JorthP , HisertKB , GarudathriJ , WolterD , HoffmanL , SinghP . Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients. Pediatric Pulmonolgy2014;49:349. [CFGD Register: PI202n] JorthP , RezayatA , HisertKB , GarudathriJ , KhanU , HamblettNM , et al. Early evolution of pseudomonas aeruginosa during cystic fibrosis infection. Pediatric Pulmonology2015;50 Suppl 41:304. [Abstract no.: 300; CFGD Register: PI202p] KhanU , Mayer‐HamblettN , Retsch‐BogartG , TreggiariM , RamseyB . Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants &amp; prior antibiotic exposure. Pediatric Pulmonology2010;45 Suppl 33:335. [Abstract no.: 326; CFGD Register: PI202f] Mayer‐HamblettN , KlosterM , RosenfeldM , GibsonRL , Retsch‐BogartGZ , EmersonJ , et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long‐term outcomes in cystic fibrosis. Clinical Infectious Diseases2015;61(5):707‐15. [CFGD Register: PI202o] Mayer‐HamblettN , KronmalRA , GibsonRL , RosenfeldM , Retsch‐BogartG , TreggiariMM , et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatric Pulmonolgy2012;47(2):125‐34. [CFGD Register: PI202i] Mayer‐HamblettN , RosenfeldM , TreggiariMM , KonstanMW , Retsch‐BogartG , MorganW , et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa. Pediatric Pulmonology2013;48(10):943‐53. [CFGD Register: PI202k] RamseyB . TOBI use in infants and children with early Pseudomonas aeruginosa infection ‐ duration of effect and epic update. Pediatric Pulmonology2005;40 Suppl 208:146. [CFGD Register: PI202a] TreggiariM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KronmalR , RamseyB , et al. Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Journal of Cystic Fibrosis2010;9 Suppl 1:S54. [Abstract no.: 209; CFGD Register: PI202e] TreggiariM , Retsch‐BogartGZ , Mayer‐HamblettN , KronmalR , KhanU , WilliamsJ , et al. Early anti‐pseudomonal infection in children with CF: study population and conduct of the &quot;EPIC&quot; clinical trial. Pediatric Pulmonology2009;44 Suppl 32:316. [Abstract no.: 299; CFGD Register: PI202c] TreggiariMM , Retsch‐BogartG , Mayer‐HamblettN , KhanU , KulichM , KronmalR , et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Archives of Paediatric and Adolescent Medicine2011;165(9):847‐56. [CFGD Register: PI202h] TreggiariMM , RosenfeldM , Mayer‐HamblettN , Retsch‐BogartG , GibsonRL , WilliamsJ , et al. Early anti‐pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemporary Clinical Trials2009;30(3):256‐68. [Abstract no.: 299; CFGD Register: PI202d] ">Treggiari 2011</a>), although the results of two further trials are awaited (<a href="./references#CD012300-bbs2-0031" title="EUCTR2011‐000801‐39‐SE . Placebo controlled clinical study to evaluate efficacy and safety of an antibody derived from hens’ eggs building a barrier in the respiratory tract against the Pseudomonas germ in order to prevent infection with Pseudomonas in patients suffering from cystic fibrosis [www.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐000801‐39‐SE]. (first received 13 December 2011). [CFGD Register: PI252c] KollbergH , LarssonA , NilssonE . Anti‐pseudomonas IGY ready for phase III. Pediatric Pulmonology2010;45 Suppl 33:343. [Abstract no.: 345; CENTRAL: 848799; CFGD Register: PI252a; CRS: 5500100000003664] LarssonA . Phase III study (IMPACTT) on anti‐pseudomonas IgY. Journal of Cystic Fibrosis2011;10 Suppl 1:S24. [Abstract no.: 92; CENTRAL: 848800; CFGD Register: PI252b; CRS: 5500100000003666] NCT01455675 . Efficacy study of igy (antibody against pseudomonas) in cystic fibrosis patients [Phase III study to evaluate clinical efficacy and safety of avian polyclonal anti‐pseudomonas antibodies (igy) in prevention of recurrence of pseudomonas aeruginosa infection in cystic fibrosis patients]. clinicaltrials.gov/show/nct01455675 (first received 2011 October 20). [CENTRAL: CN‐01533433; CFGD Register: PE252e; CRS: 8286130] SchusterA , BendJ , HoibyN , VerdePE , RottmannA , LarssonA , et al. Clinical study to evaluate an anti‐Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011‐000801‐39). Journal of Cystic Fibrosis2019;18:S23. [Abstract no.: WS12‐5; CENTRAL: CN‐01990653; CFGD Register: PI252d; CRS: 12181829; EMBASE: 2001976053] ">Larsson 2011</a>; <a href="./references#CD012300-bbs2-0030" title="Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Azithromycin for early Pseudomonas infection in cystic fibrosis: the Optimize randomized trial. American Journal of Respiratory and Critical Care Medicine2018;198(9):1177‐87. [CFGD Register: MA31b; DOI: 10.1164/rccm.201802‐0215OC; PUBMED: 29890086] Mayer‐HamblettN , Retsch‐BogartG , KlosterM , AccursoF , RosenfeldM , AlbersG , et al. Erratum: azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial [Erratum: Azithromycin for early Pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial (American Journal of Respiratory and Critical Care Medicine (2018) 198 (1177–1187) DOI: 10.1164/rccm.201802‐0215OC)]. American Journal of Respiratory and Critical Care Medicine2019;199(6):809. [CENTRAL: CN‐01967101; CFGD REgister: MA31d; CRS: 11932900; DOI: 10.1164/rccm.201802‐0215OC; EMBASE: 2001700512; PUBMED: 30874457] NCT02054156 . Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis [Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis: the OPTIMIZE multicenter, placebo‐controlled, double‐blind, randomized trial]. clinicaltrials.gov/show/NCT02054156 (first received 2014 February 04). [CENTRAL: CN‐01543461; CFGD Register: MA31c; CRS: 8295539] RamseyBW , Retsch‐BogartGZ , KlosterM , BuckinghamR , HamblettNM . Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial. Pediatric Pulmonology2017;52 Suppl 47:380‐1. [Abstract no. : 434; CFGD Register: MA31a] ">OPTIMIZE 2018</a>). The included trial was adequately powered to identify differences in its primary outcomes (time to first severe pulmonary exacerbation and proportion of PA positive cultures at each quarter). However, by excluding participants who did not fulfil the inclusion criteria for this review, these results may now be underpowered to show a difference. The risk of bias was deemed to be low across all domains with the exception of 'other bias'. Participants could be enrolled up to six months after a PA positive culture and could have had up to one course of eradication therapy during that time. This may have had an effect on the efficacy of the intervention, either biasing it towards participants who had previously undergone eradication or conversely biasing it towards participants with only a short lag between PA identification and the commencement of treatment. We have therefore stated that there is an unclear risk of 'other bias'. </p> <p>The nature of the trial as a four‐way factorial trial meant that participants in each of the cycled and culture‐based therapy groups did not receive equal treatment. In our population subset 53.8% of participants in the cycled group and 52.2% of participants in the culture‐based group received oral ciprofloxacin in addition to their inhaled tobramycin. Further breaking down the analysis into four groups would further reduce the numbers available for each comparison. </p> <p>Since this trial was conducted in young children many were unable to expectorate sputum. Most respiratory sampling in the trial relied on oropharyngeal swab cultures and the reliability of oropharyngeal cultures to reflect the microbial populations of the lower respiratory tract is limited (<a href="./references#CD012300-bbs2-0032" title="ArmstrongDS , GrimwoodK , CarlinJB , CarzinoR , OlinskyA , PhenlanPD . Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatric Pulmonology1996;21(5):267‐75. ">Armstrong 1996</a>). This may have caused false‐positive and false‐negative results in the sampling, resulting in detection bias, though it is likely that this bias would be equally applied to both groups. Ongoing treatment with anti‐pseudomonal antibiotics theoretically may have a suppressive effect on the growth of PA such that it could not be detected, particularly in OPC. However, the interval of treatment makes this less likely, since the sputum density of PA increased almost back to pre‐treatment levels during off‐treatment intervals in a study of intermittent tobramycin administration in participants chronically infected with PA (<a href="./references#CD012300-bbs2-0021" title="BirnbaumHG , GreenbergP , FinkelsteinS , BerndtE , OttoKL , MontgomeryAB , et al. Economic analysis of hospitalization and home IV anti‐pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI®). Pediatric Pulmonology1998;Suppl 17:273. [CENTRAL: 792738; CFGD Register: PI120f; CRS: 5500100000003553] BowmanCM . The long‐term use of inhaled tobramycin in patients with cystic fibrosis. Journal of Cystic Fibrosis2002;1 Suppl 2:S194‐8. [CENTRAL: 451888; CFGD Register: PI120cc; CRS: 5500100000002389; PUBMED: 15463834] BurnsJL , VanDalfsenJM , ShawarRM , OttoKL , GarberRL , QuanJM , et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Journal of Infectious Diseases1999;179(5):1190‐6. [CENTRAL: 161606; CFGD Register: PI120i; CRS: 5500100000000895; PUBMED: 10191222] CaseyS , RamseyB , BorowitzD . Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents. 13th International Cystic Fibrosis Congress; 2000 June 4‐8; Stockholm, Sweden. 2000:172. [CENTRAL: 302945; CFGD Register: PI120ff; CRS: 5500100000001685] EngerC , RothmanK , KylstraJW . Mortality rates during 2 years of treatment with intermittent inhaled tobramycin (TOBI) in CF. Pediatric Pulmonology1999;Suppl 19:339‐40. [CENTRAL: 291292; CFGD Register: PI120m; CRS: 5500100000001353] FielS , VanDevanterD , YuX . Effect of tobramycin solution for inhalation on pulmonary function decline rates in exacerbating and stable CF patients. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P195. [CENTRAL: 354406; CFGD Register: PI120s; CRS: 5500100000001933] FielSB . Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients. European Respiratory Journal2000;16 Suppl 31:1545. [CENTRAL: 415647; CFGD Register: PI120dd; CRS: 5500100000002265] GellerDE , PitlickWH , NardellaPA , TracewellWG , RamseyBW . Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest2002;122(1):219‐26. [CENTRAL: 404033; CFGD Register: PI120bb; CRS: 5500100000002214] GraffGR , GordonDC , VanDalfsenJM , BurnsJL . Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI®) study. Pediatric Pulmonology2000;Suppl 20:283. [CENTRAL: 793580; CFGD Register: PI120p; CRS: 5500100000003564] HazinskiTA . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Journal of Pediatrics1999;135(1):130. [CENTRAL: 165714; CFGD Register: PI120j; CRS: 5500100000000909; EMBASE: 1999019576; PUBMED: 10428654] KonstanMW , VanDevanterDR . Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis. Pediatric Pulmonology2001;Suppl 22:305. [CENTRAL: 362193; CFGD Register: PI120v; CRS: 5500100000001991] KylstraJW , BowmanCM , MeyerU , MontgomeryAB , SchaefflerB , StewartP , et al. Who benefits more? An age‐stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin. Netherlands Journal of Medicine1999;54 Suppl:S83. [CENTRAL: 291415; CFGD Register: PI120k; CRS: 5500100000001449] LeLorierJ , PerreaultS , BirnbaumH , GreenbergP , SheehyO . Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clinical Therapeutics2000;22(1):140‐51. [CENTRAL: 275378; CFGD Register: PI120o; CRS: 5500100000001232; PUBMED: 10688397] LiPumaJJ . Microbiological and immunologic considerations with aerosolized drug delivery. Chest2001;120(3 Suppl):118S‐23S. [CENTRAL: 356379; CFGD Register: PI120x; CRS: 5500100000001971; PUBMED: 11555566] MacLeodDL , NelsonLE , ShawarRM , LinBB , LockwoodLG , DirkJE , et al. Aminoglycoside‐resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long‐term, intermittent, inhaled tobramycin treatment. Journal of Infectious Diseases2000;181(3):1180‐4. [CENTRAL: 302968; CFGD Register: PI120n; CRS: 5500100000001702] MossR , KylstraJW , MontgomeryAB , GibsonR . Who benefits more? An analysis of FEV1 and weight in adolescent (age 13‐&lt;18) CF patients using inhaled tobramycin (TOBI). Pediatric Pulmonology1999;Suppl 19:243. [CENTRAL: 291469; CFGD Register: PI120k; CRS: 5500100000001497] MossRB . Administration of aerosolized antibiotics in cystic fibrosis patients. Chest2001;120(3 Suppl):107S‐13S. [CENTRAL: 368291; CFGD Register: PI120y; CRS: 5500100000002023] MossRB . Long‐term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest2002;121(1):55‐63. [CENTRAL: 377132; CFGD Register: PI120aa; CRS: 5500100000002049; PUBMED: 11796432] NickersonB , MontgomeryAB , KylstraJW , RamseyBW . Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients. Pediatric Pulmonology1999;Suppl 19:243‐4. [CENTRAL: 291479; CFGD Register: PI120l; CRS: 5500100000001506] OttoKL , MontgomeryAB , LinA , RamseyBW . Seasonality of hospitalization for pulmonary exacerbations and lower respiratory tract infections in Phase III tobramycin solution for inhalation (TOBI®) trials. Pediatric Pulmonology1998;Suppl 17:273. [CENTRAL: 795752; CFGD Register: PI120e; CRS: 5500100000003601] QuanJM , VasiljevM , SchaefflerB , PhelpsC , BurringtonC , MeyerU . Treatment for exacerbation only does not arrest progressive lung function decline in CF. Netherlands Journal of Medicine1999;54 Suppl:S84. [CENTRAL: 291523; CFGD Register: PI120g; CRS: 5500100000001545] QuittnerA , GordonD , YuX . Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P326. [CENTRAL: 614345; CFGD Register: PI120t; CRS: 5500100000003153] QuittnerAL , BuuA . Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology2002;33(4):269‐76. [CENTRAL: 379174; CFGD Register: PI120z; CRS: 5500100000002059; PUBMED: 11921456] QuittnerAL , BuuA , GordonD . Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials. Pediatric Pulmonology2001;Suppl 22:349. [CENTRAL: 362214; CFGD Register: PI120w; CRS: 5500100000002002] RamseyB , BurnsJ , SmithA . Safety and efficacy of Tobramycin Solution for Inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials. Pediatric Pulmonology1997;Suppl 14:137‐8. [CENTRAL: 385760; CFGD Register: PI120c; CRS: 5500100000002121] RamseyBW , BowmanMC , MontgomeryAB , SmithAR , TOBI Study Group. Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy. 21st European Cystic Fibrosis Conference; 1997 Jun 1‐6; Davos, Switzerland. 1997:144. [CENTRAL: 291527; CFGD Register: PI120b; CRS: 5500100000001548] RamseyBW , BowmanMC , Vasiljev‐KM , SmithAR , TOBI Study Group. Results of phase 3 aerosolized tobramycin studies for chronic intermittent therapy. 21st European Cystic Fibrosis Conference; 1997 Jun 1‐6; Davos, Switzerland. 1997:144. [CENTRAL: 291528; CFGD Register: PI120a; CRS: 5500100000001549] RamseyBW , PepeMS , QuanJM , OttoKL , MontgomeryAB , Williams WarrenJ , et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis Inhaled Tobramycin Study Group. New England Journal of Medicine1999;340(1):23‐30. [CENTRAL: 158508; CFGD Register: PI120d; CRS: 5500100000000883; PUBMED: 9878641] RosenfeldM , EmersonJ , Williams‐WarrenJ , PepeM , SmithA , MontgomeryAB , et al. Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics2001;139(3):359‐65. [CENTRAL: 384105; CFGD Register: PI120ee; CRS: 5500100000002077; PUBMED: 11562614] TaylorCJ . Nebulised high dose Tobramycin (TOBI) in adolescents with cystic fibrosis. Pediatric Pulmonology2001;Suppl 22:291. [CENTRAL: 362226; CFGD Register: PI120u; CRS: 5500100000002008] VanDevanterD , HouK , YuX . Effect of tobramycin solution for inhalation (TOBI®) on long term rates of lung function decline in Pseudomonas aeruginosa infected cystic fibrosis (CF) patients with mild to moderate lung disease. Pediatric Pulmonology2000;Suppl 20:298. [CENTRAL: 793150; CFGD Register: PI120q; CRS: 5500100000003557] VanDevanterD , YuX , KonstanMW . Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients. 24th European Cystic Fibrosis Conference; 2001 Jun 6‐9; Vienna, Austria. 2001:P172. [CENTRAL: 354463; CFGD Register: PI120r; CRS: 5500100000001964] ">Ramsey 1999</a>). </p> <p>Using GRADE we found that the overall quality of the evidence varied from very low to moderate across the outcomes presented in the summary of findings table. We deemed most outcomes to provide moderate‐quality evidence, downgraded only because the trial only includes children. We cannot be certain if the results would be reproducible in an adult population. We deemed the quality of evidence for pulmonary function to be very low due to the fact that younger children were unable to perform spirometry and so there was imprecision in the results from low participant numbers and missing data. Specifically, we deemed the quality of the evidence for our primary outcome to be moderate suggesting there is probably an improvement in time to recurrence after cycled therapy. The quality of evidence for secondary outcomes was moderate, with the exception of pulmonary function which was deemed to be very low meaning that we are uncertain whether there is an effect. </p> </section> <section id="CD012300-sec-0114"> <h3 class="title" id="CD012300-sec-0114">Potential biases in the review process</h3> <p>A potential source of bias in the review process is the lack of a formal definition of eradication in CF clinical trials. The included trial did not formally assess the success of initial eradication therapy; however, a sample was obtained three weeks after therapy commenced. Participants with a positive result at this stage were given an extra 28 days of TIS. We have therefore defined eradication as a negative PA sample at this three‐week time point since a later cut‐off would add another treatment variation for participants who underwent 56 rather than 28 days of TIS. However, we note that since this sample was taken whilst treatment was ongoing, suppression of PA (rather than true eradication) may have occurred. Indeed, in discussion with the authors of the ELITE trial, which we had anticipated including, it became evident that for this reason they did not send microbiological samples after the first 28 days of treatment. </p> </section> <section id="CD012300-sec-0115"> <h3 class="title" id="CD012300-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other studies or reviews which recommend strategies to prevent recurrence of PA following successful eradication. </p> <p>However, it is of note that a previous Cochrane Review examining antibiotic strategies for eradicating PA in people with CF, also found that cycled therapy was superior to culture‐based therapy (<a href="./references#CD012300-bbs2-0071" title="Langton HewerSC , SmythAR . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD004197.pub5] ">Langton Hewer 2017</a>). The authors of that review used different primary outcomes to ours and included adjustment for participant age in their analyses, which may account for some of the differences found. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012300-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012300-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012300-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 1 Time to next isolation of PA in participants PA negative at visit 2." data-id="CD012300-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 1 Time to next isolation of PA in participants PA negative at visit 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 2 Time to next isolation of PA in participants PA negative at visit 3." data-id="CD012300-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 2 Time to next isolation of PA in participants PA negative at visit 3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 3 FEV1 (L): absolute change from baseline." data-id="CD012300-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 3 FEV<sub>1</sub> (L): absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 4 FEV1 (L): relative change in from baseline." data-id="CD012300-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 4 FEV<sub>1</sub> (L): relative change in from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 5 FEV1 % predicted: absolute change from baseline (% predicted)." data-id="CD012300-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 5 FEV<sub>1</sub> % predicted: absolute change from baseline (% predicted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 6 FEV1 % predicted: relative change from baseline (% predicted)." data-id="CD012300-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 6 FEV<sub>1</sub> % predicted: relative change from baseline (% predicted). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 7 FVC: absolute change from baseline (L)." data-id="CD012300-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 7 FVC: absolute change from baseline (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 8 FVC: relative change from baseline (L)." data-id="CD012300-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 8 FVC: relative change from baseline (L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 9 Time to next exacerbation." data-id="CD012300-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 9 Time to next exacerbation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 10 Number of participants with a pulmonary exacerbation." data-id="CD012300-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 10 Number of participants with a pulmonary exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 11 Frequency of pulmonary exacerbations (at end of trial)." data-id="CD012300-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 11 Frequency of pulmonary exacerbations (at end of trial). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 12 Weight (kg): absolute change from baseline." data-id="CD012300-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 12 Weight (kg): absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 13 Weight percentile: absolute change from baseline." data-id="CD012300-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 13 Weight percentile: absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 14 Height (cm): absolute change from baseline." data-id="CD012300-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 14 Height (cm): absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 15 Height percentile: absolute change from baseline." data-id="CD012300-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 15 Height percentile: absolute change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 16 Adherence: number not returning trial medication." data-id="CD012300-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 16 Adherence: number not returning trial medication. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 17 Adherence: number not returning tobramycin." data-id="CD012300-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 17 Adherence: number not returning tobramycin. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 18 Number of severe adverse events." data-id="CD012300-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 18 Number of severe adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 19 Isolation of newly resistant PA." data-id="CD012300-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 19 Isolation of newly resistant PA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 20 Isolation of newly mucoid PA." data-id="CD012300-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 20 Isolation of newly mucoid PA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012300-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/urn:x-wiley:14651858:media:CD012300:CD012300-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_t/tCD012300-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Cycled versus culture‐based therapy, Outcome 21 Isolation of novel resistant gram negative organisms." data-id="CD012300-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Cycled versus culture‐based therapy, Outcome 21 Isolation of novel resistant gram negative organisms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/media/CDSR/CD012300/image_n/nCD012300-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012300-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: cycled versus culture‐based antibiotic therapy for preventing recurrence of infection with Pseudomonas aeruginosa </span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cycled antibiotic therapy compared with culture based antibiotic therapy for preventing recurrence of infection with PA in cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children (aged 1 to 12 years) with CF and a newly isolated PA infection </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: cycled administration of antibiotics </p> <p><b>Comparison</b>: culture‐based administration of antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Culture‐based therapy</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Cycled therapy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to next isolation of PA</b> </p> <p>Follow‐up: up to 583 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The participants in the culture‐based therapy group were twice as likely to have experienced a recurrence by their final study visit than those in the cycled group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR <b>2.04</b> (1.28 to 3.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR was calculated from individual patient data.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> </b>: change from baseline (L) </p> <p>Follow‐up: median 494 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in FEV<sub>1</sub> in the culture based group from baseline was +0.26 L. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The change in FEV<sub>1</sub> in the cycled group was 0L higher (0.09 L lower to 0.09 L higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>1,2,3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between the two groups was not statistically significant P = 0.97.</p> <p>FEV<sub>1</sub> was also measured in percent predicted which showed a non‐significant difference between the groups at up to two years. MD 0.7% (‐4.33% to 5.73%) P = 0.79. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pulmonary exacerbations</b>: frequency </p> <p>Follow‐up: up to 583 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of pulmonary exacerbation in the culture‐based group was 1.1.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean frequency of pulmonary exacerbation in the cycled group was 0.18 pulmonary exacerbations per person lower (0.51 lower to 0.14 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The difference between the groups was not statistically significant, P = 0.27.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to chronic PA</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not measured.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: severe adverse events (total) </p> <p>Follow‐up: 18 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>231 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><br/> (90 to 256) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.65</b> (0.39 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was no significant difference between groups for the total number of participants experiencing a serious adverse event P = 0.11. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of novel bacteria</b>: isolation of novel gram negative organisms </p> <p>Follow‐up: median 494 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>276 per 1000</b><br/> (185 to 414) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> </p> <p><b>1.0</b> </p> <p>(0.67 to 1.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant difference in the acquisition of novel organisms between treatment groups. P = 0.98 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CF</b> : cystic fibrosis; <b>CI</b> : confidence interval; <b>HR</b> : hazard ratio; <b>RR</b> : risk ratio; <b>PA</b>: <i>Pseudomonas aeruginosa.</i> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded once due to indirectness. The trial only includes children between the ages of one and 12 years and was not designed to answer the specific question posed in this review. </p> <p>2. Downgraded once due to risk of bias from incomplete outcome data. Although this was taken from individual patient data, only 131 of the 253 participants included in our subset, were included in this analysis. </p> <p>3. Downgraded once from small participant numbers which do not meet the optimum information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: cycled versus culture‐based antibiotic therapy for preventing recurrence of infection with Pseudomonas aeruginosa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/full#CD012300-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012300-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cycled versus culture‐based therapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to next isolation of PA in participants PA negative at visit 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.28, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to next isolation of PA in participants PA negative at visit 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.21, 3.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FEV<sub>1</sub> (L): absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.10, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.09, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 FEV<sub>1</sub> (L): relative change in from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.09, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 FEV<sub>1</sub> % predicted: absolute change from baseline (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.41 [‐6.90, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [‐2.66, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐5.07, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [‐4.33, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV<sub>1</sub> % predicted: relative change from baseline (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.09, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.07, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.07, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 FVC: absolute change from baseline (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.07, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.03, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.06, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 FVC: relative change from baseline (L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.03, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.05, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Time to next exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.78, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of participants with a pulmonary exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.70, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Frequency of pulmonary exacerbations (at end of trial) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Study‐defined pulmonary exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.51, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Any additional antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.85 [‐1.46, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Weight (kg): absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.13, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.24, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.46, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [‐0.38, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Weight percentile: absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [‐1.20, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.23, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐4.51, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐4.48, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Height (cm): absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.29, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.74, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.77, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.09, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Height percentile: absolute change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [‐0.35, 4.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐2.23, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [‐1.32, 4.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.07 [‐1.12, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adherence: number not returning trial medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.84, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.63, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.53, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.45, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adherence: number not returning tobramycin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Up to 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Up to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.83, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Up to 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Number of severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Respiratory</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.32, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.23, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Gastro‐intestinal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.11, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Metabolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.02, 9.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 Musculoskeletal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 Nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.04, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 Skin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 6.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 Other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.36, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.39, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Isolation of newly resistant PA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Isolation of newly mucoid PA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Isolation of novel resistant gram negative organisms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Up to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.67, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cycled versus culture‐based therapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012300.pub2/references#CD012300-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012300.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012300-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012300-note-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012300-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012300-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012300-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012300\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012300\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012300\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012300\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012300\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012300.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012300.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012300.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012300.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012300.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719065108"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012300.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719065112"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012300.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddfa1bdbd1be4',t:'MTc0MDcxOTA2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 